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Overview 
 
This portfolio thesis comprises of three parts: a systematic literature review, an 
empirical report and a reflective statement.    
 
Part one is a systematic review in which literature relating to the empirical paper is 
reviewed. Due to a paucity of literature about reasons to participate in male reproductive 
health trials (RHTs), the broader area of reasons to participate in clinical trials, from a 
non-clinical sample, was reviewed. The review attempts to determine reasons why 
‘healthy’ people participate in clinical trials and compares the findings with literature on 
reasons why patients participate. Recommendations are then made for future clinical 
trial recruitment strategies. 
 
Part two is an empirical paper encompassing two studies. Study one aimed to test 
hypotheses about factors that influence male participation in RHTs, specifically 
masculinity and altruism. Comments from participants about their own idiosyncratic 
reasons were then used to triangulate findings. Study two aimed to complement study 
one by exploring experiences of men participating in a RHT. Thematic constructions of 
stigma, altruism and masculinity were considered within a decision-making framework.   
 
Part three comprises of appendices, including a reflective summary drawing on all 
aspects of the research process.  
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PART ONE: 
 
 
 
Reasons for participation in clinical trials: 
A systematic review of published literature from non-clinical populations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This paper was written in accordance with guidance for authors for the journal ‘Trials’ 
(Appendix 1).    
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Reasons for participation in clinical trials:  
A systematic review of published literature from non-clinical populations  
 
Abstract  
Background: Clinical trial participation is often under-resourced and little is known 
about reasons why non-clinical populations take part in clinical trials. The aim was to 
systematically review published literatures on reasons to participate in clinical trials for 
a non-clinical population.   
Methods: Key electronic databases (CINAHL, PsychINFO, PsychARTICLES, 
Medline, Scopus, and Web of Science) were searched using specific terms and articles 
were included based on inclusion and exclusion criteria. The quality of included articles 
was assessed using standardised criteria and data was extracted systematically using a 
data extraction form.  
Results: 12 articles were included in the review (10 quantitative, 2 qualitative) and 
quality assessment scores ranged from 50% to 83%. The review identified the following 
reasons for trial (non) participation; age, gender, educational level, SES, personality, 
health status, time constraints, perceived burden, organisational credentials, 
understanding of research process, altruism, benefits, finances, personal interest and 
risks.    
Conclusions: Comparisons were made between clinical and non-clinical populations’ 
reasons for clinical trial participation. It seems both groups weigh up advantages and 
disadvantages of entering a trial when making a decision to participate, although the 
influence of these reasons would appear to be quite idiosyncratic. Recommendations for 
future research are made.    
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Introduction 
Clinical trials are essential for today’s requirement for evidence-based practice. The 
National Health Service (NHS) [1] defines the importance of clinical trials: ‘Doctors, 
other health professionals and patients need evidence from clinical trials to know which 
treatments work best. Without this evidence, there is a risk that people could be given 
treatments that have no advantage, that waste NHS resources and that might even be 
harmful’. For the purpose of this review, clinical trials are conceptualised as ‘a research 
study in human volunteers to answer specific health questions’ [2]. This definition of 
clinical trials includes studies in a variety of locations (e.g. hospitals, universities, 
public places, people’s homes) and utilising a range of methods (e.g. medical treatment, 
mailed survey, telephone interview). 
  
Despite the importance of clinical trials, participation is often under-resourced [3]. An 
understanding of the facilitators and barriers to participation is required to enhance 
strategies for recruitment to clinical trials. A recently conducted a systematic literature 
review into clinical trials and concluded that the following strategies could improve 
recruitment; telephone reminders; use of opt-out, rather than opt-in; procedures for 
contacting potential trial participants and open designs [4]. However, the review did not 
account for potential differences between clinical and non-clinical populations. 
 
Published literature on factors found to influence participation in clinical trials from the 
viewpoint of patients1 and clinicians has also been reviewed [3]. A range of barriers to 
clinical trials for both patients and clinicians were identified (Table 1). However, the 
review did not identify drivers for patient participation. 
                                                          
1 Patients and clinicians were recruited from the following settings; cancer, cardiovascular, smoking 
cessation, HIV/AIDS, obstetrics, surgery, child health, mental health, osteoporosis, multiple sclerosis, 
stroke, insomnia, diabetes and burns. 
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 Table 1. Barriers to clinical trial recruitment for patients and clinicians.  
Barrier 
 
Number of identified 
papers (studies)  
 
Patient concerns  
Additional demands on the patient:  
1. Additional procedures and appointments  13 (13) 
2. Travel problems and costs  8 (8) 
Patient preferences for a particular treatment (or no 
treatment) 
 
15 (15) 
Worry about uncertainty of treatment or trials  9 (9) 
Patient concerns about information and consent  27 (26) 
 
Clinician as barrier to patient participation 
 
Protocol causing problem with recruitment  14 (13) 
Clinician concerns about information provision to 
patients  
 
7 (7) 
Clinician influencing patient decision not to join  6 (6) 
 
Barriers to clinician participation 
 
Time constraints  9 (8) 
Lack of staff and training  11 (11) 
Worry about the impact on doctor-patient relationship  12 (11) 
Concern for patients  9 (9) 
Loss of professional autonomy  7 (5) 
Difficulty with the consent procedure  9 (8) 
Lack of rewards and recognition  5 (4) 
Insufficiently interesting question  2 (2) 
 
Reasons why patients chose to (or not to) participate in 26 clinical trials were studied 
[5]. The results suggested that a potential participant has a ‘personal balance account’ to 
assess before consenting to take part [5] (Figure 1). This can be calculated by the 
physical and emotional value a participant hopes to gain from taking part in the study, 
compared to non-participation, minus the risks and time burden they expect from the 
trial. The model suggests that background factors, beliefs, locus of control, attitudes, 
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expectations and perceptions have an inter-related influence on the decision to 
participate in a trial. When all these factors are considered, patient’s decisions become 
‘quite predictable’ [5].  
 
Figure 1. The adapted Health Belief Model.  
 
 
Factors that influence participation for a non-clinical population were not reviewed [3] 
[5]. Non-clinical populations are also important for clinical trials and in some cases are 
specifically required (e.g., research into ‘healthy’ people, control groups and 
preventative studies). A search of key electronic databases (Web of Science, 1970 to 
present [6]; Medline, 1950 to present [7]) suggested that to date, there has not been a 
systematic review of the literature on the reasons to take part in clinical trials from a 
non-clinical sample perspective. Non-clinical participant’s reasons to, or not to take part 
in clinical trials are likely to differ from those of patient groups, due to the absence of 
factors related to their medical condition; such as their symptoms, treatments and 
contact with medical staff. As non-clinical populations are less likely to gain from 
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participation (i.e. new treatments), financial incentives and altruism 2  may be more 
influential factors in the decision making process.  
 
In the absence of knowing about ‘healthy’ participants, it is also difficult to draw firm 
conclusions about which factors specifically influence clinical groups. Therefore, a 
review of published literature on the barriers and drivers to clinical trial participation for 
a non-clinical population is required, to formulate recruitment strategies for both clinical 
and non-clinical populations.         
 
Objectives 
The reviewed aimed to identify the reasons to, and not to, take part in clinical trials for a 
non-clinical sample.  
 
Questions 
1. What reasons are associated with participation in clinical trials for a non-clinical 
sample? 
2. What reasons are associated with non-participation in clinical trials for a non-
clinical sample? 
 
Method 
Data sources  
A systematic search of the literature was carried out. Guidelines from the Centre for 
Reviews and Dissemination were used to inform the review [8]. The following 
electronic databases were searched; CINAHL, MEDLINE, PsychARTICLES, SCOPUS 
and ISI Web of Science. Ranges of databases were searched to ensure that a holistic 
                                                          
2 A voluntary effort to benefit a recipient, with no expectation of reward.  
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approach to the research question was taken, including medical, social science and 
psychological perspectives. Table 2 outlines the search terms inputted into searched 
electronic databases. 
 
Selection criteria 
Studies were eligible for inclusion if they provided information about reasons for, or 
against, taking part in clinical trials. Clinical trials included all studies with human 
volunteers that aimed to answer specific health questions. Clinical populations were not 
eligible due to the potential for reasons for participation and non-participation being 
primarily linked to specific clinical issues and treatments. Studies including both 
genders were eligible to ensure a representation of potential gender influences. Studies 
involving children and people with carers were excluded due to the potential impact of 
development and differences in consenting to study participation. Qualitative and 
quantitative methodologies were included to ensure a broad and detailed review of the 
literature. Only peer reviewed full-text studies were included to increase scientific 
rigour. Funding and resource limitations prevented translation or the purchase of 
articles. Studies published before 2000 were excluded to ensure that data was recent, 
and studies published from the United Kingdom were within NHS reforms of the past 
decade, following the ‘Saving Lives: Our Healthier Nation’ White Paper [9].        
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Search strategy  
Table 2. Search terms.  
KEY TERMS (OR) 
Reasons (AND) Subject Terms: 
“Determinants”, “Attitude*”, “Decision*”, “Process*”, 
“Strateg*”, “Reason*”, “Factor*”, “Incentive*”, “Benefit*”, 
“Difficult*”, “Problem*”, “Obstacle*”, “Barrier*”, 
“Willing*”, “Ready”, “Able”, “Readiness”, “Agree*”, 
“Offered”, Facilitat*”, “Motivat*”, “Incentive*”, “Drivers” 
Clinical Trial (AND) Title: 
“Health”, Medical”, “Trial”, “Experiment”, “Study”, 
“Studies”, “Research”, “Survey”. 
Participation (AND) Title: 
“Participation”, “Subject”, “Volunteer”, “Participant” 
Subject Headings: 
“Research Subject Recruitment”, “Research Subjects”, 
“Research Subject Retention”, “Researcher-Subject 
Relations”. 
Patients (NOT) Title: 
“Patients”, “Clinical Sample” 
 
Data extraction 
Data related to the aims of the review were recorded on a data extraction form designed 
specifically for the purposes of the review (Appendix 2). The structured form was used 
for both qualitative and quantitative studies. 
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Quality assessment  
An adapted version of a ‘Quality Checklist’ [10] was used to guide the quality 
assessment of the quantitative studies (Appendix 3). The checklist was used due to its 
high reliability and validity scores for both randomised and non-randomised studies, 
and its ability to provide a full quality profile of papers. Items 4, 14, 15, 19, 21 and 23-
25, were removed from the checklist as they specifically assessed intervention studies. 
Studies eligible for review did not always involve interventions as the review focused 
upon participant’s reasons for taking part in clinical trials. The ‘Quality Framework’ 
[11] was used to guide the assessment of studies with qualitative methodology 
(Appendix 4). The ‘Quality Framework’ underwent a rigorous validation process and 
was designed for the UK government.     
 
Data synthesis  
Reasons for participation reported by included publications were grouped into themes. 
Themes were then compared across all included publications.         
 
Results 
Details of included and excluded studies 
Figure 2 illustrates the selection process. Initial searches yielded 1541 articles. Of those, 
1523 articles were excluded based on their title or abstract showing that they did not 
meet inclusion criteria. Seven articles were not freely available and 36 articles were re-
printed. After analysis of the reprints, 24 papers were excluded based on inclusion and 
exclusion criteria. Articles were excluded due to the following reasons; 1) Participants 
were a clinical sample, 2) Participant population was too specific or difficult to 
generalise to a general population, 3) The article did not investigate reasons for 
participation.  
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Design of included studies  
Studies with a range of designs were included in the review. Nine studies used 
questionnaires’ [14, 15, 17, 18, 20, 21, 22, 23, 24] and two studies used semi-structured 
interviews [16, 19]. Study 11 analysed transcriptions from semi structured focus group 
discussions [12].      
 
Measures 
Included studies used different measures to evaluate reasons for (not) participating in 
clinical trials. Study 9 used the Minnesota Multiphasic Personality Inventory-2 (MPMI-
2, [13]). Study 2 and 5 analysed the characteristics of respondents from public health 
questionnaires in Sweden and Denmark [14, 22]. The remaining studies used bespoke 
questionnaires or interviews, specifically designed to assess factors that influenced 
participation in respective clinical trials.   
 
Participants  
Total numbers of participants ranged from 18 to 13,604. Participants from included 
studies were all healthy volunteers sampled from non-clinical populations.  
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Willingness to participate in clinical trials 
The measurement of willingness to participate in clinical trials varied across included 
studies. Studies 1, 4, 6 and 12 [21, 17, 16, 24] reported a percentage of participants who 
were willing to take part in future (hypothesised) clinical trials, with a median 
willingness of 25-46%. Studies 2, 3, 5, 7 and 9 [14, 15, 22, 23] reported percentages of 
participants who had consented to take part in a (actual) clinical trial, with a median of 
49-56%. Studies 4, 10 and 11 [17, 19, 12] did not report the number of people who 
chose not to participate.  
 
Age  
Participants in studies included for review ranged in age from 15 to 84 years old. The 
vast majority of participants were over 18 years old although study 6 included two 
participants under the age of 16 [16]. Studies 4, 9 and 10 did not report the ages of 
participants, although they all indicated that participants were over 18 years old [17, 18, 
19]. Study 4 reported that the majority of participants were 18-year-old first year 
university students [17]. Studies 6 (m=38), 8 (m=31) and 11 (male m=32.3, female 
m=42.7) reported the mean age of participants but made no comparisons with 
willingness to take part in clinical trials [16, 20, 12].  
 
Studies 1, 2 and 3 found significant correlations between the age of participants and 
willingness to take part in clinical trials [21, 14, 15]. Younger participants were more 
likely to participate in study 1. Fifty seven percent of participants aged 18-34 were 
willing to take part in a clinical trial, in comparison to 49% for the 35-64 age group, 
47% for the age 45-64 group and 30% for the over 65 age group [21]. Study 1 also 
found people aged 35-64 were overrepresented, in comparison to predictions made from 
statistics about the general population. Study 3 found that younger people were much 
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more likely to participate in clinical trials than older people [15]. In contrast, study 2 
found that younger people were under-represented in a sample of respondents to a 
postal survey. The response from people under the age of 35 was much less than would 
be predicted by statistics for the general population (< 35, general population; m = 
31.2%, f=29.9%, study population, m = 24.5%, f = 25.5%). The response rates for age 
groups ranging from 45 to over 65 were representative of the general population [14]. 
Study 5 found that people in their thirties were significantly more likely to mail their 
response to a survey as opposed to a telephone interview [22].   
 
Studies 7 and 12 found no relationship between the age of participants and their 
reported willingness to participate in future clinical trials [23, 24]. 
 
Gender  
Studies 1 [21] and 7 [23] reported higher percentages of female participants (66% and 
51% respectively) and study 10 [19] reported a higher percentage of male participants 
(55%). Three studies identified gender as a significant factor in response rates. 
Significantly more females responded to a Swedish public health questionnaire in study 
2 [14] than the statistics for the general population would predict (sample f=54.4%, 
m=45.6%, general population m=50.5%, f=49.5%). Study 5 [22] found that more 
females than males were willing to respond to mailed questionnaires about health and 
well-being (m=54.2%, f=62.0%). In contrast, more males than females replied to an 
invitation to participate in a health research project (m=63%, f=59.7%, study 3). Study 
12 found no differences between genders in reported willingness to take part in future 
trials [24].  
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Study 11 found different themes between genders in relation to clinical trial 
participation. Males were more concerned about the business, economics and reputation 
of research and researchers. In contrast, females were more concerned about the 
researcher-participant relationship and the value of the research project to the 
community [12]. 
 
Studies 4, 6 and 9 [17, 16, 18] did not publish information about the gender of 
participants and study 8 [20] had an all male sample. Studies 1, 7 and 10 [21, 23, 19] 
made no comparisons between the number of males and females approached or 
differences in their reported willingness.      
 
Educational Level  
Three studies found significant correlations between educational level and willingness 
to participate in clinical trials. Study 1 found that 50% of participants with a college or 
graduate degree would be willing to take part, as opposed to 44% of participants who 
had only a high school education [21]. Study 2 found that the representation of people 
with lower levels of education was lower in the sample than general population statistics 
would predict (31% to 36%) [14]. Study 7 also found that participants with lower levels 
of education were significantly less likely to participate in future surveys [23].  
 
In contrast, no differences in educational level were found between participants and 
non-participants in study 5 [22]. Study 12 [24] also reported educational levels had no 
bearing on participants willingness to participate in future clinical trials  
 
 
 
 
 
27 
 
Social and economic status (SES) 
Six studies reported participant’s earnings, employment or social status. Sixty percent of 
the participants in study 8 were unemployed [20]. In study 11, all participants either 
were in full time education, employment or retired [12]. Studies 8 and 11 [20, 12] did 
not compare employment or SES with willingness to participate in clinical trials.  
 
Study 1 compared participant’s earnings with levels of earnings predicted from census 
data. A slightly higher representation than expected of people earning $20,000-$40,000 
per annum returned surveys. Study 1 also found a significant positive relationship 
between higher earnings and willingness to participate in clinical trials. Forty two 
percent of people earning less than $20,000 were willing to participate, in comparison to 
52% of people who were earning over $40,000 [21]. Study 3 assigned each participant a 
‘deprivation level’ based upon where they lived. They found that people from areas of 
high deprivation, in comparison to people from areas of low deprivation, were more 
likely to refuse to participate in the trial (HD; 62.3% refused, LD; 47.0% refused) [15].  
 
In contrast, studies 7 and 12 found no relationship between employment or occupation, 
and willingness to participate in future clinical trials [23, 24].  Studies 6, 8 and 11 
reported educational levels but made no comparisons with participants’ willingness to 
take part in clinical trials [14, 18, 10]. Study 4 participants’ were all students at the same 
educational level [15]. Studies 3, 9 and 10 did not report educational levels [13, 16, 17].  
 
Finances  
Two studies reported that financial incentives were offered to people for participation. 
Study one and eight paid participants $5 and $75 respectively to complete a survey [21, 
20]. Participants in study eight received $3000 to enter phase 1 of a drug trial. Of the 
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nine studies eligible for review, only studies 8 and 9 mentioned money as a reason to 
take part in clinical trials [20, 18]. Eighty four percent of participants in study 8 stated 
that money was a reason for taking part in the clinical trial [20]. Participants in study 9 
rated ‘getting free medication’ as the least important reason for taking part in a clinical 
trial. However, participants rated the reason ‘getting free medication’ on average 3.6, in 
between unsure ‘3’ and agree ‘4’ [18].  
 
Business and compensation were two of the main themes in male focus group 
discussions in study 12 [24]. Men felt that the research industry is only concerned with 
making money, “some...research is just for some people (researchers) to make money”. 
One participant suggested that money was not the most important incentive, “don’t 
consider a quick buck, don’t give me $100 to be part of a research study that doesn’t 
have to do with bettering …illness” [24].      
 
Altruism 
Six studies found altruism to be a key reason for taking part in clinical trials [21, 20, 18, 
19, 12, 24]. Study 1 reported that people with a friend or relative with an illness being 
researched in a trial (58%), were significantly more likely to participate than those who 
did not (39%) [21]. Participants in study 9 rated ‘doing something that will help others’ 
as the greatest incentive for taking part in a clinical trial (Mean score = 4.51, 4 agree, 5 
strongly agree) [18].  
 
The authors of study 11 described how the overall value of clinical trials to society was 
a key theme for females discussing clinical trials in a focus group [12]. The following is 
a quote used by the authors to illustrate the theme of ‘value of research’, “If you tell me 
that researching this will help save millions of lives then I’m more apt to do it than if 
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it’s some rare thing and it might one day help somebody. So if you can make a closer 
link to how my participating can actually help, I’ll be more likely to want to get 
involved.” The authors of study 10 concluded that altruism, or ‘medical research as a 
public good’, was a key theme related to people’s willingness to take part in clinical 
trials [19] and concluded that participants’ ‘are likely to cooperate with a voluntary 
endeavour only if they can produce a moral account of their actions.’    
  
In contrast, only 10% of participants in study 8 reported that ‘helping society or a sick 
person’ was a reason for taking part in the clinical trial [20]. Study 12 also found that 
participants who held the belief that clinical trials helped to improve other people’s 
physical health, were no more willing to take part in clinical trials than those who did 
not hold this belief [24]. The remaining six studies did not mention altruism as a reason 
for participation.  
 
Health status 
Five studies reported that a person’s health status bore little or no relation to their 
willingness to participate in a clinical trial. Study 1 found no relationship between 
participants reported willingness to enter a clinical trial and their own health status (in 
contrast to the health of a friend or relative as mentioned earlier) [21]. Study 2 reported 
no significant differences in health care utilization costs (medical expenses per person) 
between people who did or did not participate in a Swedish health survey [14]. Only 3% 
of participants in study 8 reported that ‘helping their own health’ was a reason for 
taking part in the clinical trial. Only two percent of participants in Study 4 reported that 
the possibility of a clinical trial identifying an unknown health problem was a reason for 
non-participation [17]. Study 12 found that there was no significant relationship 
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between willingness to take part in a clinical trial and participants who were, or were 
not, diagnosed with a chronic disease, or receiving general medical treatment [24].   
 
In contrast to studies 1, 2, 4, 8 and 12, three studies found an association between 
people’s health status and a willingness to participate in clinical trials. Study 7 found a 
negative relationship between willingness to enter a clinical trial and good health status. 
People who rated their health status as fair or poor were significantly less likely to take 
part in future surveys [23]. Study 9 allowed participants to write comments at the end of 
a survey into ‘factors that influence participation’. Eleven participants cited that ‘risk to 
your own health’ was a reason for not taking part in clinical trials [18]. Participants over 
75 years old in study 3 reported that they were ‘too old’ to participate. Although they 
did not specify that this had an impact upon their health, it is possible that ‘too old’ was 
related to their perceived health status [15]. Four studies did not mention participant’s 
health as a reason for taking part in clinical trials [22, 16, 12, 19].    
 
Benefits 
Studies 1, 4, 8, 9 and 12 examined the relationship between willingness to enter a 
clinical trial and beliefs about benefiting from participation. All five studies noted that 
participants did not think that clinical trials participation would be beneficial to them. In 
Study 1, people who believed that the effectiveness of treatment assigned to participants 
was ‘always the best for the patient’ were more willing to participate (47.6%) compared 
to those who thought that it was ‘never the best for the patient’ (38.7%). Differences 
between the groups were not statistically significant, as the vast majority of participants 
(85%) believed that the treatment assigned ‘might be the best for the patient’ [21]. 
Study 9 found similar results when researching different reasons given for taking part in 
clinical trials. People who stated that they would not be willing to participate were less 
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likely to agree that the trial would ‘help to delay a disease’ in comparison to people who 
were willing to take part [18]. Only 2% of participants in study 4 and 3% in study 8 
believed that participation in a health trial would be beneficial for them [20, 17]. Study 
12 suggested that there was no difference in willingness to take part in clinical trials 
between those who believed that participation would, or would not, improve their own 
physical health [24].   
 
Risk of entering a trial   
Studies 1, 3, 4, 7, 9, 10 and 11 described how perceived risks of entering a clinical trial 
were reasons for not taking part. Study 1 suggested that people’s attitudes towards the 
use of human subjects in clinical trials affected their decision to participate. Fifty two 
percent of people who favoured the use of human subjects stated that they would be 
willing to participate, in comparison to 32% of people who did not favour the use of 
human subjects [21]. People’s attitudes regarding the priorities of researchers also 
seemed to be a reason for participation. Nearly 50% of people who thought the ‘well 
being of participants was more of a priority for researchers than the results of the study’ 
were willing to participate.  
 
Study 9 also found differences in the appraisal of risk for people who had or had not 
taken part in clinical trials. People who had not taken part in clinical trials (mean=3.46) 
were more likely to agree that ‘experiencing side effects of medication’ was a reason for 
not participating than people who had previously taken part (mean=2.99). Eleven 
participants also gave feedback at the end of the survey suggesting that ‘risks to your 
health’ was a barrier to participation [18].  
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Studies 3, 7 and 9 identified perceived risks to personal privacy as a reason for not 
taking part in a clinical trial. Forty-five percent of participants in study 3 did not want a 
nurse coming to their house and 39% did not want to give away personal details [15]. 
Study 7 found that privacy concerns were a significant univariate predictor of non-
participation in future health surveys [23]. In contrast, non-respondents in study 9 least 
agreed with ‘losing one’s privacy’ as a drawback to participation [18].  
 
Participants’ in study 4 noted specific concerns about the particular clinical trial, with 
28% of people stated that the fear of ‘getting blood drawn’ was a reason for not taking 
part [17].  
 
Themes regarding risk and safety were prominent in studies 10 and 11. ‘Eagerness to 
serve the public good was tempered by some wariness’. In order to enter a trial, 
participants must ‘feel confident that their decision was not taken irresponsibly or 
stupidly’ [19]. Participants in study 11 were less willing to take part in clinical trials as 
they thought ‘potentially harmful effects of research are often not known by 
researchers’ [12].   
 
Understanding of the research process 
Studies 1, 3 and 12 found prior participation in clinical trials significantly increased the 
likelihood of future trial participation. Study 3 recruited participants from a clinical trial 
running at the same time [15]. Study 1 described a significant relationship between prior 
and future clinical trial participation. Fifty five percent of people who had previously 
taken part in a clinical trial reported that they would be willing to do so again in the 
future. This is in comparison to the 45% of people willing to participate with no prior 
experience of clinical trials [21]. Multiple-choice questions assessed knowledge about 
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the rationale for clinical trials and the research process. Knowledge about the research 
process, but not the rationale, was significantly correlated with willingness to participate 
in a clinical trial [21]. Participants in study 12 rated a significantly higher willingness to 
take part in future clinical trials if they had previously participated (previous 
participation, m=4.4, no participation, m=1.4, 0-8, 8 very unwilling, p<0.001) [24].  
 
Studies 3, 4, 6 and 9 highlighted a lack of understanding of the research process as a 
barrier to participation. The authors of study 3 [15] concluded that a misunderstanding 
of the nature and purpose of the trial was one reason for non-participation, based on an 
analysis of the responses to the open questions at the end of the study. Twenty three 
percent of participants in study 4 suggested the reason they did not take part in an 
associated clinical trial was that they ‘had not heard about it’. Fifteen percent of the 
participants also stated that they did not understand the clinical trial [17].  
 
Study 6 evaluated an information leaflet for a clinical trial. The authors suggested that a 
misunderstanding of the research process could have been a reason for non-
participation. Sixty five percent of participants gave a correct explanation of informed 
consent after reading the leaflet and participants seemed to have problems answering 
questions on the effectiveness of new treatments versus old treatments [16].  
 
Hearing about the good things that come from a clinical trial (m = 4.36), or an 
informational meeting about the clinical trial (m = 4.00), were reasons cited in study 9 
that people agreed or strongly agreed would help participation [18]. Even though most 
people agreed with both statements, the informational meeting was the method that 
people least agreed with and hearing about the good things was the method that most 
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people agreed with (six methods). Therefore, it might be type of information, rather than 
amount, which is important [18].      
 
Organisational and professional credentials   
Four studies assessed the influence of beliefs about the organisation conducting the trial 
on a participant’s willingness to take part (23, 19, 12, 24). Study 7 reported that an 
understanding of the organisation conducting the clinical trial was a significant reason 
for participation. Results suggested that people would be twice as likely to take part in a 
clinical trial if they knew the sponsor or organisation [23]. Study 12 found no difference 
in willingness to participate in clinical trials between those people who believed that 
clinical trials served the pharmaceutical industry’s interests, and those who did not [24].  
The authors of studies 10 and 11 found the reputation of researchers to be a key theme 
in interviews regarding clinical trial participation and found that ‘visible signs of 
reasonable practice’ were important to participants [19, 12]. These included ‘warrants of 
trust’; such as logos and affiliations with trusted organisations; such as universities and 
the National Health Service. In comparison, pharmaceutical companies were deemed 
less trustworthy [19]. Male participants in focus groups were particularly concerned 
about the reputation of the research facility. Participants’ described how they wanted ‘a 
reputable person, an expert, the best doctor and equipment, and a reputable and clean 
hospital that specialises in the research area’ [12].  
 
Relationships with researchers came out as an important theme in the two qualitative 
studies’ exploration of clinical trial participation [19, 12]. Interviews suggested that 
most participants were able to establish ‘swift trust’, as interpersonal trust was 
‘institutionally located’. Participants also commented favourably on encounters, which 
had characteristics of friendship, respect and politeness [19]. Female participants in 
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study 11 described how they wanted the researcher to focus on them as a ‘human 
being’, to make them feel comfortable, to treat them well and not as though they were 
guinea pigs’ [12].     
 
Time constraints and perceived burden  
Four of the studies eligible for review reported time constraints or the burden of 
participation as a reason for not taking part in a clinical trial. Attitudes about not having 
enough time, or being burdened by participation, were both significantly correlated with 
the decision not to participate in future clinical trials in study 7 [23]. Having too many 
other commitments and not enough time to take part in clinical trials were also reported 
as reason in open-ended questions in studies 3 and 9 [15, 18]. Fifty eight percent of 
participants in Study 4 also supported these findings suggesting that they were too busy 
to take part in a clinical trial [17].       
  
Personal Interest 
Studies 3, 4 and 7 specifically asked people about their interest in clinical trials. Thirty 
one percent of participants in study 3 said they were not interested in the clinical trial 
and 27% said that they were not interested in research in general. More men (33%) than 
women (22%) reported being disinterested in clinical trials [15]. Fifteen percent of 
participants in Study 4 also reported disinterest in clinical trials as a reason for non-
participation [17]. Study 7 identified the saliency of a study as a reason for 
participation, with 92% of participations reporting that they would take part in a clinical 
trial if it ‘strongly’ or ‘somewhat’ interested them. However, regression models 
employed by the study suggested saliency was not a significant predictor of future trial 
participation [23]. Nine people responding to an open-ended question in study nine said 
that an interest in ‘learning about medicine and the body’ was a reason for taking part in 
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clinical trials [18]. Study 1 found people who agreed that diverse types of people 
participated in clinical trials, were significantly more likely to take part in future trials 
than those who did not [21].   
 
Personality 
Only study 9 looked at personality traits as a factor that could influence participation in 
clinical trials. The authors of study 8 conducted a personality assessment (MMPI-2 
[13]) on participants of a pre-running clinical trial. No relationships were found between 
personality subscales and clinical trial participation. However, 50% of participants had 
elevated scores on a variety of subscales of the test. The authors were unable to draw 
firm conclusions from the results but suggested clinical trial participants might vary in 
personality traits, in comparison to the public [20].     
 
Reasons to participate in clinical trials (non-clinical sample) reported in this review are 
summarised in Table 4. 
 
Quality of included articles  
The maximum score achievable on the quantitative quality assurance checklist was 18 
(Appendix 5). Criteria were rated on a dichotomous Y (1) / N (0) scale. The mean 
overall quality rating was 12.6 with a range of 8 – 15 criteria met. Poorly scored items 
(<8) on the whole included; description of sample characteristics; clear description of 
principal confounders; description of the characteristics of sample lost to follow up; 
representativeness of recruitment population; representativeness of the participant 
population; control or adjustment for different lengths of follow up; reliability and 
validity of outcome measures; and sufficient power to detect a significant effect.  
Included in all of the quantitative articles (n=10) were; the objective of the study; a 
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description of the main outcomes in the method; a description of the main findings; 
representative staff, places and facilities; clear description of ‘data dredging’ where 
applicable; appropriate statistical tests; and cases and controls were recruited at the 
same time where applicable.  
The maximum achievable score on the qualitative quality assurance checklist was 18 
(Appendix 7). Both articles provided analysis next to relevant extracts from transcripts 
and both scored 14/18. Study 11 compared three previous qualitative studies and 
therefore scored poorly on items regarding the initial coding of data. Study 10 scored 
poorly on items relating to the discussion of results generalisability and diversity of 
accounts.  
 
Two Trainee Clinical Psychologists assessed the quality of seven quantitative articles 
(Appendix 6) and one qualitative article (Appendix 7). Items on the quantitative quality 
assurance checklist had an average inter-rater reliability score of K=0.83. 3  
 
 
                                                          
3
 Kappa Statistic 
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Table 4. Reasons for (not) participating in clinical trials from non-clinical populations 
Reason Study findings 
Demographic factors 
 
Age S1: Younger participants were more willing to enter clinical trial. 35-64 
over represented in comparison to prediction from population statistics. 
S2: Participants <35 were underrepresented in study in comparison to 
population statistics. 
S3: Older participants (>75) correlated to belief ‘too old to enter clinical 
trial’. 
S5:  Participants aged 30-39 more willing to respond via post vs. 
telephone. 
S7 & 12: No effect of age. 
 
Gender S1&7: Higher % female participants. 
S3&10: Higher % male participants. 
S2:  Lower % male responders than predicted by population statistics. 
S5:  Greater % female willingness to respond to postal questionnaire. 
S12: No significant differences in gender willingness. 
S11: Different themes for males and females. 
 
Educational level  S1: Higher education = greater willingness. 
S2: Less lower educated participants than expected from population 
statistics. 
S7: Lower educated participants were significantly less willingness to 
participate. 
S5&12: No differences between participants with different educational 
levels. 
 
Social and 
economic status 
S1: $20,000-$40,000 over represented in respondents. Greater earnings = 
greater willingness to enter trial. 
S3: Participants from high deprivation areas were less likely to enter 
clinical trial. 
S7&12: No difference between employment / occupation and willingness. 
 
Participant characteristics 
 
Personality 
 
Study9: No personality scale predictors. 50% participants had elevated 
scores on different MMPI-2 subscales. 
Health status S1,2,4,8&12: No association between health status and trial participation 
or willingness 
S7: Good health status = less willing to enter clinical trial. 
Practical issues 
 
Time constraints 
and perceived 
burden  
 
S3&9: Participants reported ‘too many other commitments’ and ‘not 
enough time’ to enter a trial. 
S7: Attitude of ‘not enough time’ or ‘burden by participation’ correlated 
with non-participation. 
S4: 58% participants reported being ‘too busy’ to enter clinical trial. 
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Organisation and 
professional 
relationships and 
credentials   
 
S7: Understanding of the organisation conducting trial had significant 
influence on participation. 
S10&11: Reputation of organisation and researchers key theme related to 
trial participation. More trust in relationships with researchers affiliated 
with trusted organisations.   
S11: Being treated as a human being and not ‘guinea pig’ was a key theme 
in trial participation. 
S12: No differences between participants that did and did not think trials 
serve the pharmaceutical industry’s interests.      
 
Understanding of 
the research 
process 
S1, 3&12: Prior trial participation predicted entering a future trial.  
S3, 4, 6 &9: Lack of understanding of research process, purpose and 
rational was a significant barrier to participation.  
 
Reasons for participation 
 
Altruism 
(helping others) 
 
S1: Participants with a friend or relative with illness studied were 
significantly more willing to enter trial than those who did not.  
S9: ‘Doing something to help others’ was rated the greatest incentive to 
enter trial. 
S11: The overall value of clinical trials to society was a key theme 
regarding trial participation. 
S10: ‘Medical research as public good’ was a key theme regarding trial 
participation.  
S8: Only 10% stated ‘helping society or sick person’ was a reason to enter 
trial. 
S12: Belief trials improve health for others were not related to willingness 
to enter clinical trial.  
 
Benefits 
 
Finance 
 
S1, 4, 8, 9 &12: Participants stated no benefits to taking part in clinical 
trials. 
 
S8: 84% participants stated money was a reason for participation.  
S9: Free medication rated as least important reason.  
 
Personal interest 
 
S3: 31% not interested in research (significantly more men not interested). 
S4: 15% not interested in research. 
S7: 92% participants would participate in trial if it ‘strongly’ or 
‘somewhat’ interested them.  
S9: 9 participants described ‘learning about medicine and the body’ as 
reason to enter clinical trial.  
 
Reasons for non-participation 
 
Risk of entering 
a trial   
S1, 3, 4, 7, 9, 10 & 11: Risks of entering a clinical trial were reasons not 
to enter clinical trial (risk to health, privacy, side effects). 
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Discussion  
Decision making model  
The review suggested that similar to patients [5], non-clinical participants assess a 
‘personal balance account’ before consenting to take part in a clinical trial. Participants 
appear to weigh up reasons to enter a trial such as altruism and personal interest, with 
reasons not to participate such as risks, time constraints and perceived burden. 
Organisational credentials, relationships with professionals and an understanding of the 
research process also affected the decision to participate, as with patients. Similarly, 
background factors such as age, gender, educational level and SES were found to 
influence the decision making process.  
 
Differences between clinical and non-clinical sample reasons to participate in clinical 
trials were also apparent. Health statuses of non-clinical populations did not appear to 
influence the decision making process as significantly as reported for patients [5]. 
Altruism and personal interest were reported as reasons to take part in clinical trials so it 
seems likely that these are important factors for patients. However, in the absence of 
benefits afforded to patients such as improved or different treatments, it is likely that 
altruism and personal interest are more significant for non-clinical populations in the 
decision making process.             
 
Correlations between willingness to participate and demographic factors often 
contradicted each other across the studies reviewed. In general, a greater number of 
studies suggested that participants, who were younger [21, 15], female [14, 21, 22, 23], 
highly educated [14, 21, 23] and from areas of low deprivation [15, 21] were more 
willing to take part in clinical trials. Males and females had different reasons for 
participating in clinical trials [12], reflecting an influence of gender on beliefs about 
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clinical trials. Further research would enable a richer understanding of how gender 
influences willingness to enter a clinical trial. Participants with lower educational levels 
may view clinical trials as an arduous academic exercise, especially long mailed 
questionnaires. In contrast, highly educated researchers or professionals undertaking 
clinical trials are more likely to have an interest, or be aware of, clinical research. 
Reasons for trial participation appear to vary across demographic groups and ‘one size 
fits all’ recruitment strategies may ‘at best be inefficient and at worst inappropriate’ [15, 
14].  
 
Personality subscales on the MMPI-2 were not significantly related to clinical trial 
participation [20]. Rather than suggest that personality factors are not related, it is more 
likely that the MMPI-2 did not assess specific personality traits related to trial 
participation, (e.g. altruism). It seems that consistent with patient groups, background 
factors influence how non-clinical participants weigh up, and assign significance to, the 
‘pros and cons’ of participation.  
 
Perceived risks associated with clinical trials were the most cited barrier to participation 
[12, 17, 18, 19, 21, 23]. Concerns about risks ‘unknown to researchers’ [12] are 
consistent with previous findings suggesting participants have a much stronger belief in 
the existence of ‘unknown effects’, than experts [26]. Perceptions of risk do not always 
correlate with measurable probabilities of risk, suggesting other factors influence risk 
perceptions [25]. Participants are significantly more inclined to participate in clinical 
trials if they trust the researcher, or respect the organisation conducting a trial [12, 19, 
23]. The findings are consistent with idea that in the absence of control over a perceived 
risk, its significance is dependent upon beliefs about the existence and reliability of risk 
management procedures [27]. Trusting the researcher and the organisation conducting 
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the trial may help reduce fears about entering a trial and potentially tip the ‘personal 
balance account’ towards participation.  
 
Not having enough time, feeling burdened and having a poor understanding of clinical 
trials are common barriers to clinical trial participation [17, 18, 23]. However, trial 
participants are much more likely to enter a future trial than people who have never 
participated [18, 21]. Although this could reflect individual preferences, trial 
participation may modify negative assumptions about clinical trials. Perceptions of 
clinical trials are likely to be anchored by particular heuristics, such as the availability 
of media reports of risks from trial participation, or representations of medical 
procedures.  
 
Altruism, benefits and personal interest were described by reviewed studies as reasons 
to participate in a clinical trial, for a non-clinical population. The authors of the two 
qualitative studies included in the review described motivations such as ‘helping 
society’ and displaying ‘moral character’ as important reasons for trial participation [18, 
19, 21]. Further research is needed for a more detailed understanding of the relationship 
between altruism and trial participation, such as how individual trials trigger an 
altruistic reaction in potential participants. It seems that altruism and personal interest 
are prominent reasons to take part in a clinical trial for people from a non-clinical 
sample, as nearly all studies found participants associated taking part in a clinical trial 
with few or no benefits [12, 15, 17, 18, 19, 20, 21, 23]. 
 
Financial incentives were only reported to be a significant reason to enter a clinical trial 
in one reviewed study (study 8). The low frequency reporting of financial drivers for 
clinical trial participation is surprising and inconsistent with previous commentaries, 
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which suggest money may be one, or even the main, reason for trial participation in a 
non-clinical sample [28]. Money can ‘attract subjects to research and overcome inertia 
and other barriers’ [28], which is consistent with the decision making model. The 
majority of included studies employed low risk methodologies (e.g. surveys); therefore, 
it may be that financial incentives were not considered necessary in relation to 
perceived barriers. In contrast, participants in study eight were recruited from a 
potentially risky drug trial that lasted 30 days. Participants were given $3000 to enter 
the drug trial and 84% suggested money was the main reason for participation. Hence, 
financial incentives seemed to outweigh the perceived barriers to trial participation.  
 
Recommendations for services  
The findings of this review have implications concerning services and practice of key 
practitioners. However, a ‘one size fits all’ strategy of recruitment is suggested to be 
inappropriate [15]. Considerations concerning the sample population may help to ensure 
efficient, effective and representative recruitment. This could include tailoring the 
language of information to the educational level of participants, or stressing particular 
factors found to be relevant to certain age groups or genders.  
 
Attitudes towards clinical trials and the appraisal of risk are important reasons in the 
decision to take part. Therefore, researchers should attempt to communicate the realistic 
risks to health and privacy to dispel potential unfounded anxieties about clinical trials. 
Concerns about trial participation are often idiosyncratic and discussing the spectrum of 
these may increase people’s negative perceptions of risks associated with participation. 
Therefore, an individualised recruitment system using individuals’ preferred methods, 
such as post, email or telephone, is likely to increase recruitment. It seems a balance 
needs to be struck between tailoring information to individuals’ preference and 
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satisfying requirements of regional ethics committees. Non-clinical participants rarely 
see benefits to clinical trials. Therefore, individualised benefits such as financial 
incentives, providing interesting findings and helping society could be stressed.   
 
Making communications more idiosyncratic may not only help to tailor information to 
particular groups of people, it may also help to increase people’s perceptions of how 
important their participation is. A more individualised approach may increase empathy 
towards the researcher or research topic and in turn promote altruistic behaviour(s).    
 
An understanding of clinical trials (including; participants’ exact involvement in the 
research process; why the trial is being conducted; the ‘good things’ that have / will 
come from the particular trial; an association with a well known and respected sponsor 
of clinical trials) was highlighted in the review as an essential factor in trial recruitment. 
Advertising and providing accessible information about clinical trials is likely to bolster 
recruitment.  
 
Limitations of the review  
Median recruitment levels (49%-56%) and willingness to participate (25%-46%) in 
clinical trials could not be compared to patient samples due to a paucity of literature on 
average recruitment levels. Direct comparisons of studies may also be invalid due to the 
diversity of clinical trials and associated idiosyncratic reasons for participation. Quality 
assessments suggested some study samples were not representative of a general non-
clinical population (e.g. sampled only previous trial participants). Ratings of willingness 
may therefore have been an artefact of the methodologies used. Future research could 
attempt to review the general populations’ attitudes towards clinical trial participation.  
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The review compared clinical trials with a wide variety of methodologies, therefore 
reasons to participate for a postal survey may not have generalised to studies with an 
invasive medical procedure.   
 
Many of the included studies did not assess for important principal confounders such as 
religious beliefs and / or beliefs about human medical testing. The samples of 
participants used in the studies were often not representative of the general population. 
Very few studies reported measures’ reliability and validity information and the 
majority of studies did not assess for the characteristics of non-respondents.   
 
Ideas for future research  
It is for future researchers to evaluate the effectiveness of the recommendations made 
for clinical trial recruitment strategies. The review identified a variety of reasons that 
influence the decision to take part in a clinical trial and presented a decision making 
model for a non-clinical sample. Further research should aim to provide a deeper 
qualitative understanding of how complex inter-relationships between reasons influence 
willingness to participate in clinical trials. Further quantitative research could also 
evaluate the influence of these reasons identified in different types of trials.  
 
Conclusions  
Reasons for participation in clinical trials from a non-clinical sample were 
systematically reviewed. Similarities and differences between patient groups were 
described and reasons for (non) participation were mapped onto a pre-existing decision 
making model [5]. Recommendations were made for future recruitment strategies and 
further research.    
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PART TWO: 
 
 
 
Male reproductive health:  
Reasons why men may choose to participate in trials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This paper was written in accordance with guidance for authors from the journal of 
‘Human Reproduction’ (Appendix 8).    
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Male reproductive health research: reasons why men may choose to participate in 
trials 
Abstract 
BACKGROUND: Male reproductive health trials (RHTs) are often under-resourced. 
Study 1 aimed to determine drivers and barriers to participation, and to test for the 
significance of demographic factors, masculinity and altruism, on willingness to take 
part in a PES (pre-ejaculatory fluid study). Study 2 aimed to qualitatively explore men’s 
reasons for participating in a PES. METHOD: Study 1: 505 men from around the world 
completed an online survey, which included demographics, perceived masculinity 
questionnaire (MQ), self-report altruism scale (AQ), and reported willingness to 
participate in a PES. Participants also commented on drivers, barriers, and the impact of 
masculinity on their reported willingness. Study 2: Five men completed a semi-
structured interview about their experience of participating in a PES, and the drivers and 
barriers to participation. Interviews were transcribed and analysed using interpretive 
phenomenological analysis. RESULTS: Ordinal regression showed that altruism, 
socio-cultural roles, age, number of children, relationship status and continent of origin 
were significantly related to willingness to participate in a PES. Qualitative comments 
in study 1 reported practical concerns as the most common barrier to PES participation. 
Beliefs about the influence of masculinity varied. In study 2, three main themes 
emerged; conflict in decision making between doing a ‘good thing’ and the shame 
associated with a ‘socially frowned upon’ act; performance anxiety, feeling ‘less of a 
man’ and ‘inadequate’; and humour and other strategies to cope with difficult feelings. 
CONCLUSION: Potential and actual participants would appear to weigh up pros and 
cons of RHT participation. The significance of pros and cons appeared to be 
idiosyncratic and influenced by background factors. Recommendations for services and 
further research are made.  
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Introduction 
Rationale 
The World Health Organisation (WHO) defines reproductive health (RH) as a state of 
complete physical, mental and social well-being, and not merely the absence of disease 
or infirmity (WHO, 2010a). RH addresses reproductive processes, functions and 
systems at all stages of life. RH therefore implies that people are able to have a 
responsible, satisfying and safe sex life and that they have the capability to reproduce 
and the freedom to decide if, when and how often to do so (WHO, 2010a). 
Reproductive and sexual ill heath accounts for 12% of the global burden of ill health for 
men (WHO, 2010b). Therefore, RH problems cause physical, mental and social well-
being difficulties for a large number of men around the world. The scale of problems 
caused by male reproductive ill health illustrates the importance of research in the area.      
 
Clinical trials are essential for researchers to provide an evidence base for practice in the 
field of RH. ‘Doctors, other health professionals and patients need evidence from 
clinical trials to know which treatments work best. Without this evidence, there is a risk 
that people could be given treatments that have no advantage, that waste NHS resources 
and that might even be harmful’ (National Health Service, 2010). Researchers need to 
recruit both participants from RH and reproductive ill health populations, in order to 
carry out these trials. 
  
However, participation rates for males in RH clinical trials are often very low (Muller, 
Rocherbrochard, Labbe-Decleves, Jouannet, Bujan, Mieusset, et al, 2004). Studies 
reporting participation rates suggest that semen collection rates range between 13% and 
19% (Muller, et al., 2004). This is unsurprising as men seek infertility treatment less 
often than women and are reported to be less committed to the treatment process 
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(McGrade & Tolor, 1981). Low participation in RH treatment is paralleled with 
findings that suggest men as a group seek professional help much less frequently than 
women for a range of health problems, including depression, substance abuse and 
physical disability (Addis & Mahalik, 2003). The National Institute for Clinical 
Excellence (NICE, 2008) recommends that research should be commissioned to 
‘establish the link between effective approaches to community engagement and longer-
term health outcomes’. NICE (2008) also specifically recommends that research should 
‘describe the theoretical links between the context, process, structure and impact of the 
activity’. Research into the area of male RH trial recruitment is therefore needed 
(Muller, et al., 2004) and recommended (NICE, 2008).    
 
Male reproductive health trial (RHT) participation research 
Very few studies have been published on factors that influence a man’s decision to take 
part in a reproductive health trial. Muller, et al, (2004) compared the characteristics of 
the partners of pregnant women for three levels of participation: completion of a refusal 
form, completion of the study questionnaire only, and agreement to complete the study 
questionnaire and give a semen sample. Men who completed the study questionnaire 
tended to be younger and better educated than those who did not. Participants who 
completed the study questionnaire and gave a semen sample were more likely to have 
experienced RH problems in their family than those who only completed the study 
questionnaire.  
 
Cultural differences in relation to participation were also found (Muller, et al., 2004). 
Participants in France, comprising of a large African community, were described as less 
likely to participate as semen collection is seen as taboo. There are problems with 
extrapolating the study’s findings to the UK National Health Service as the study was 
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conducted in France. The study was also limited to partners of pregnant women, 
therefore not representing single men and men without children.  
 
There has been more research into the drivers and barriers of semen donation. There are 
different factors that influence men’s willingness to participate in RHTs and donate 
semen. Daniels, Curson and Lewis (1996a) suggested that personal circumstance, laws 
of anonymity and laws regarding potential recipients all influenced a man’s decision to 
donate semen. Altruism 4  is reported to be the predominant motivation for semen 
donation (Handelsman, Dunn, Conway, Boylan, & Jansen, 1985). Motivation to donate 
semen has also been found to increase if attention has been brought to RH because of 
sterility among a man’s relatives (Lalos, Daniels, Gottlieb, & Lalos, 2003). Edelmann 
(1996) described how different studies have found different typical donor types. One 
study found the typical donor was aged 41 and was not intent on having any more 
children, while another study found that the typical donor was aged 23 and had not been 
in any steady relationships. 
 
A systematic review of published literature from 2000 until 2010 also suggested that 
age, education, gender and altruism were factors associated with willingness to take part 
in clinical trials in general, for a non-clinical sample (Sanderson, in preparation). The 
review suggested that men who were younger (Trauth, Musa, Siminoff, Jewell & Ricci, 
2000; Williams, Irvine, McGinnis, Murdo & Crombie, 2007) and had higher levels of 
education (Trauth, et al, 2000; Carlsson, Merlo, Lindstrom, Ostergren, & Lithman, 
2006; Beebe, Jenkins, Anderson, & Davern, 2008) were more willing to take part in a 
clinical trial.  
                                                          
4 A voluntary effort to benefit a recipient, with no expectation of reward. 
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Gender differences have been found in clinical trial participation. An analysis of 
responders to a postal public health questionnaire survey in Sweden suggested that there 
was a significantly higher ratio of female to male responders than would be expected 
from population statistics (f=54.4%, m=45.6%) (Carlsson, Merlo, Lindstrom, Ostergren, 
& Lithman, 2006). Feveile, Olsen & Hogh (2007) also found that significantly more 
females than males responded to both a postal and telephone health survey in Denmark 
(m=54.2%, f=62.0%). 
 
Masculinity 
A gender difference in participation in RHTs suggests that being a man, or masculinity5, 
is potentially a relevant factor when assessing the drivers and barriers to participation. 
Social constructionist theory suggests that masculinity is defined by people and their 
context (Moynihan, 1998). Courtenay, McCreary & Merighi (2002) describe how health 
related beliefs and behaviours are ways of demonstrating femininities and masculinities, 
in the same way as language and sports. Courtenay et al, (2000) suggest that to 
demonstrate masculinity entails behaviours that undermine ones health. 
  
Independence, self reliance, strength, robustness and toughness are masculine 
stereotypes (Golombok & Fivush, 1994). Gender stereotypes can provide ‘collective, 
organised and dichotomous’ meanings of gender and often become widely shared 
beliefs about who women and men innately are (Pleck, 1987).  Males are encouraged to 
conform to these stereotypes by society (Bohan, 1993) and this then reinforces self-
fulfilling prophecies of such behaviour (Crawford, 1995). Health behaviours may be 
one of the practices through which masculinities (male and female) are differentiated 
from one another (Messerschmidt, 1993). 
                                                          
5 The qualities which are considered to be typical of men 
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Inhorn (2004) explored the connection between masculinity and the emphasis put on 
different aspects of health, for example greater emphasis on muscle mass than illness. 
She concluded that disorders such as infertility and erectile dysfunction are seen as 
particularly emasculating. In a similar finding, Dixon-Mueller (1993) found that sexual 
behaviours play a key role in defining gender roles and identities. There are also gender 
differences in experiencing infertility. Women often perceive it as a devastating stigma6 
that jeopardises their sense of being a ‘complete’ woman (Whiteford & Gonzalez, 
1995). Men on the other hand often experience infertility as a threat to masculinity and 
sexual potency (Webb & Daniluk, 1999).  
  
Moynihan (1998) describes a dynamic element between gender and health care 
professionals. Masculinity is ‘not what we are, but what we do in social situations’ 
(Moynihan, 1998).  Doctors often refer to men’s bodies with mechanical analogies 
(therefore reinforcing this belief), for example, a man who has lost a testicle to cancer 
may be told that ‘one cylinder is as good as two.’ Moynihan proposes that by looking at 
gender rather than biological sex, from a constructionist point of view, practical changes 
can be made in the doctor-patient relationship and highlight problem areas in medical 
practices / research that need further investigation. 
 
Altruism  
As previously mentioned, altruism has also been found to influence clinical trial 
participation. People with a friend or relative with an illness researched in a clinical trial 
were significantly more likely to participate than those who did not (58%:39%: Trauth, 
                                                          
6 Characteristics or activities that society considers to be deviant or distasteful   
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et al, 2000). ‘Doing something that will help others’ was reported by participants as the 
greatest incentive for taking part in a clinical trial (Kennedy & Burnett, 2007).  
 
Research suggests that altruism is an influential factor in the decision to take part in 
clinical trials (Sanderson, in preparation) and donate semen (Handelsman, Dunn, 
Conway, Boylan, & Jansen, 1985). It is therefore likely that altruism also influences a 
man’s decision to take part in a RHT. Philosophically the identification of truly 
altruistic behaviour has been questioned. Lawler and Thye (1999) propose that the 
decision to engage in helping behaviours is based on a social exchange; people try to 
maximise the ratio of social rewards to social costs. Similarly, Eisenberg and Fabes 
(1991) suggest that altruistic behaviours are often an attempt to relieve personal 
distress; such as arousal and disturbance caused by seeing somebody in distress. The 
empathy-altruism hypothesis states that people with higher levels of empathy are more 
likely to engage in altruistic behaviours (Bateson, 1991).  
 
Sociobiologists have argued that altruism is a method of ensuring the continuation of 
one’s genes, by helping one’s children or kin group (Wilson, 1978). Wilson (1978) 
suggests that altruism is genetically coded differently for males and females: Women, 
who arguably have limited and recognisable genetic interests, tend to display altruism 
more readily within the family. In comparison, men have the potential to reproduce on a 
much wider scale and therefore have a greater interest in contributing to the well being 
of the wider system.  
 
Pandey and Griffitt (2006) have disputed the evolutionary perspective on gender 
differences. They concluded that depending on the methodology, some studies have 
shown that males demonstrate a higher degree of displayed helpfulness, while other 
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studies have suggested that women have greater altruistic tendencies. Eagly and 
Crowley (1986) argue that sex differences in the expression of altruism could be due to 
gender-defined roles. For example, females are often socialised to avoid engaging in 
high-risk behaviours, which are often required for what society deems as altruistic 
behaviour. Dougherty, (1983) described how the elicitation of altruistic behaviour is 
affected by the sex-role appropriateness or inappropriateness of the requester. In 
summary, a study examining impact of research assistant gender found that the male 
expert and female non-expert recruited the most participants. Dougherty (1983) 
concluded that higher recruitment levels were due to the perceived appropriateness of 
sex-roles.  
 
In summary, the literature suggests that demographic factors (age, education, ethnicity, 
relationship status & number of children), masculinity and altruism influence 
participation in clinical trials and semen donation. It has also been suggested that 
altruism can be modulated by gender differences (Wilson, 1978; Pandey & Griffitt, 
2006; Ullian, 1984; Dougherty, 1983). Therefore, it is reasonable to suggest that 
demographics, altruism and masculinity not only influence a man’s decision to take part 
in a RHT, but also influence each other. To date there has been no empirical research 
into the relationship between these factors and willingness to participate in RHT. A 
greater understanding of the influence of these factors could guide future research into 
strategies to improve recruitment into male RHTs. 
 
 
 
 
Aim of study one 
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To assess the relationship between Masculinity and Altruism scores (Independent 
variable) and ratings of willingness to participate in a RHT (Dependent variable). To 
record and control for demographic information.   
   
The secondary aim was to collect participants’ subjective opinions about drivers / 
barriers and perceived impact of masculinity on their willingness to participate in a 
RHT.  
 
Hypotheses 
1. The higher the score on the Masculinity Scale, the less willingness there will be to 
participate in the RHT. 
2. The higher the score on the Altruism Scale, the greater the willingness there will be 
to participate in the RHT.     
 
Method  
Recruitment 
The local Post Graduate Medical Institute Ethics Board granted ethical approval for the 
study in March 2009 (Appendix 9). Participants were recruited via advertisements 
placed on emails to Post Graduate Students at the local university, a male health 
message board (MSN) and a social networking website (Facebook, 2009 to 2010). The 
advertisement showed a woman holding a board quoting ‘Are you man enough?’ and 
gave a brief summary of the study (Appendix 10). Information about the study 
accompanied email and message board advertisements (Appendix 11). When clicked 
upon, the advertisement directed participants to an online survey. Survey information 
was presented and participants were asked to indicate their consent to take part 
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(Appendix 12). To be eligible for the study, participants had to confirm that they were 
male and over 18.  
 
Measures 
The survey consisted of 65 questions, including demographics, masculinity, altruism, 
willingness to participate in a reproductive health trial, and the barriers / drivers to 
participating in a reproductive health trial (Appendix 13).  
 
Masculinity was measured using the Perceived Masculinity Questionnaire (MQ: 
Chesebro & Fuse, 2001). It was created after reviewing literature on the beliefs and 
behaviours that construct the concept of masculinity in Western society. It comprises 10 
dimensions including; physiological energy, physical characteristics, gender-related 
socio cultural roles, subjective gender-identity, gender-related age identity, gender-
related racial and national identities, idealized masculinity, sexual preference, lust and 
male eroticism (Appendix 14 7 ). Internal consistency of all MQ subscales had a 
Cronbach’s alpha of 0.68. Criterion validity was tested by calculating that males scored 
significantly higher than females on all subscales apart from ‘gender related age 
identity’ and ‘gender related racial and national identities.’ 
 
The Self Report Altruism Scale (AQ: Rushden, Chrisjohn, & Fekken, 1981) consists of 
20 items measuring altruistic actions that benefit strangers and organisations. Rushden, 
Chrisjohn & Fekken (1981) assessed the validity of the AQ by correlating scores with 
peer ratings of altruism. Peer ratings had an internal consistency Cronbach alpha of 
0.89, (N=416) and had a significant positive correlation with the AQ, r (86) = 0.35, (P 
<0.001). The predictive validity of the AQ was tested by correlating results with eight 
                                                          
7
 Description of each dimension on the MQ 
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‘altruistic’ responses, for example volunteering. The AQ positively and significantly 
related to 4/8 measures and was found to predict a linear combination of the eight 
measures, r = 0.40 (P < 0.01). 
 
Procedure 
After giving informed consent (ticking agreement to complete survey), participants 
were required to select their age (18–27, 28-37, 38-47, 48-57, 58+), educational 
attainment (SAT’s, GCSE’s, NVQ, Vocational Course, A Levels, University Graduate, 
Post Graduate), country/ continent of origin (United Kingdom, Europe, Africa, Asia, 
Americas, Australasia), ethnicity (White, Mixed, Asian, Black, Other), relationship 
status (Single, Long Term Relationship, Married, Divorced, Widowed),  and number of 
children (0, 1, 2, 3+) from a set of multiple choice tick boxes.   
 
Participants were then required indicate their response on a 7-point Likert Scale for each 
question of the MQ and a 5-point Likert Scale for each question of the AQ. Parameters 
of the MQ were dependent on the nature of the question, for example, parameters 
‘strongly desirable’ to ‘strongly undesirable’ were used for questions about the 
desirability of certain masculine traits. Parameters of the AQ Likert Scale assessed the 
frequency of altruistic behaviours (e.g. donated blood), from ‘never’ to ‘always’ / ‘very 
often’.  
  
A poster advertisement (Appendix 13) for a trial investigating ‘pre-ejaculatory fluid’ 
(PES) was presented to participants. It required men to give a semen sample to help 
answer questions about fertility and condom use. The advertisement offered participants 
a personal sperm count and £10 expenses. A 5-point Likert scale then asked participants 
to hypothetically rate their interest in taking part in the study. Participants were 
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instructed to rate their willingness to take part in the PES, if it was located in their area. 
The scale ranged from 1; ‘not interested at all’ to 5; ‘very interested’. The PES paper is 
currently in submission (Killick, Leary, Trussell, & Guthrie).    
 
Comment boxes asked for reasons for and against PES participation. Survey 
respondents were also asked to comment on how masculine they perceived participating 
in the PES to be. The final question asked participants to leave their contact details if 
they would be willing to discuss their experience of taking part in the PES. Results of 
interviews are discussed in study 2.           
 
Participants 
The recruitment process is described in figure I. Between March 2009 and March 2010, 
3,878,133 impressions of the advertisement were presented on Facebook (Facebook, 
2009 to 2010) and it was clicked on 1,896 times (0.049% of the total impressions). 
Statistical data regarding recruitment is not available for emails or message board 
advertisement (MSN). People who received an email were invited to forward the email 
to male contacts who they believed might be interested in participating in the online 
survey. The information page was viewed by 990 people. Seventeen participants were 
excluded as they stated that they were female. A total of 521 men completed the survey. 
Sixteen participants were removed due to recording 10 or more blanks on the 
questionnaire, leaving 505 participants. Three hundred and fifty participants left 
comments for reasons not to participate (in the PES), 342 left reasons to participate (in 
the PES), and 222 left comments about how masculine the advertised PES was deemed 
to be. Fifty-two participants reported contact details, implying a willingness to 
participate in, and discuss, their experience of the PES.  
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Figure I8. Participant recruitment process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample size requirements and analysis procedure 
An ordinal regression was used to test the significance of relationships between the 
dependent variable (willingness to participate) and independent variables (subscales on 
the masculinity and altruism scales). The analysis adjusted for amalgamated categorical 
demographic co–variables such as educational level and age. Distributions of responses 
for the five categories of the dependent variable were not easily predicted. There may 
                                                          
8 Roman numerals used due to author guidelines for ‘Human Reproduction’  
Social network website 
recruitment 
  
3,878,133 impressions 
1,896 views 
Message board and email 
recruitment 
990 visits to online  
survey information page  
521 men begin online survey 
505 men complete  
online survey 
350 ppts commented on 
barriers to PE study 
342 ppts commented on 
drivers to PE study  
222 ppts commented on 
masculinity perception of PE 
study  
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17 female ppts excluded 
16 ppts with 10 or more 
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have been a 20% response for each of the five categories on the Likert scale outcome, or 
there may have been a much more skewed distribution (previous research has reported 
low rates of willingness to participate in RHTs; Muller, et al., 2004). In the latter case, 
the study would have needed a much larger sample size for adequate statistical power 
when modelling predictors than in the former case. However, based on sample sizes 
typically used in log-linear modelling of categorical data, a sample size target of 500 
was set. One-way analysis of variance and Spearman’s rho correlations checked for 
differences and correlations between demographic factors and variables of masculinity 
and altruism.         
 
Participants’ comments about barriers, drivers and perceived masculinity of 
participation in the PE study were coded, and frequencies counted. This procedure was 
also independently undertaken by a Trainee Clinical Psychologist and results compared. 
Results revealed thirteen differences in coding (7 barriers, 2 drivers & 4 perceived 
masculinity), which were discussed and re-coded after agreement.   
 
Results 
Descriptive Statistics 
Participants were grouped according to demographics and the following groups were 
collapsed for the purpose of analysis; UK and Europe; Africa and Asia; 58 – 67 and 
67+; and Divorced or Widowed. The highest percentage of participants were aged 18 – 
27 (57.4%), from Europe (44.7%), white (86.0%), university graduates (30.7%), single 
(47.2%) and had no children (70.2%). Demographic characteristics of participants are 
shown in Tables III to VIII.  
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Masculinity  
The mean total score on the MQ was 198 (SD=21) with a range from 138 to 245. 
According to Cheesebro & Fuse (2001), the mean was in the ‘average masculinity 
group’ (186-225) and was slightly lower than an average score of 205 (Appendix 14). 
Table I shows the descriptive statistics for the individual subscales of the MQ. Subscale 
scores were similar to normative data (within one standard deviation of the mean) 
provided by Cheesbro & Fuse (2001) (Appendix 14). Results suggest that average 
masculinity scores were slightly lower in comparison to normative data from a US 
sample (N=331), although differences were not significant.   
 
Table I. MQ subscale descriptive statistics.  
MQ Subscale Mean SD Min score Max Score N* 
Physiological 
Energy 
17.6 4.5 4 28 497 
Physical 
Characteristics  
18.0 3.3 6 28 503 
Socio-Cultural Roles 13.5 7.9 4 28 500 
Idealized Gender 22.1 3.5 10 28 494 
Sexual Preference 24.6 4.6 6 28 496 
Subjective Identity 20.3 4.5 4 28 495 
Age Identity 24.5 3.8 4 28 495 
National Identity 25.2 4.7 8 28 496 
Lust 13.0 3.6 4 24 499 
Male Eroticism 19.7 4.1 4 28 493 
*N Number of participants who answered all questions on the subscale   
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Altruism 
Forty-two participants’ scores on the AQ were removed due to missing data leaving 463 
valid responses. Mean score was 46 (SD=11) with a range from 20 to 75. Mean altruism 
score was 9 points lower than results from five samples (M=55, range=52-57, SD=11) 
published by Rushden, Roland & Fekken (1981), which indicates that the sample was 
(on average) less altruistic than students from the US.   
 
Willingness to participate in the pre-ejaculatory fluid study (PES) 
Table II reports frequencies and percentages for each rating of willingness to participate 
in the PES. All 505 participants completed the willingness question as participants who 
did not answer the question were excluded during preliminary analysis of results.  
   
Table II. Frequency and percentages for levels of willingness to participate in the PES  
Level of Willingness  
 
N Percentage 
1 Not at all willing 189 37.4 
2 70 13.9 
3 Neutral  95 18.8 
4 90 17.8 
5 Very willing  61 12.1 
 
Demographic factors and willingness to participate in reproductive health trial 
Tables III to VIII present willingness to take part in the PES in relation to age, 
education, continent of origin, relationship status, number of children and ethnicity. 
Higher numbers indicate a greater reported willingness to take part in the PES.   
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Table III. Cross table of participants’ age and willingness to take part in the PES.  
Willingness 18-27 28-37 38-47 48-57 58+ 
1 Not willing 30% (87) 49% (38) 44% (34) 48% (20) 57% (8) 
2 17% (49) 13% (10) 5% (4) 12% (5) 7% (1) 
3 Neutral 22% (63) 13% (10) 19% (15) 14% (6) 7% (1) 
4 19% (55) 12% (9) 21% (16) 17% (7) 21% (3) 
5 Very willing  12% (36) 13% (10) 12% (9) 10% (4) 7% (1) 
Total No. 290 77 78 42 18 
Sample % 57.4% 15.2% 15.5% 8.3% 3.7% 
 
Ordinal regression was used to test the relationship between age groups and ratings of 
willingness to participate in the PES. The results showed that lower ratings of 
willingness to take part in the PES were more likely as participants’ age increased. Age 
was found to be significantly9 related to ratings of willingness to take part in the PES 
(Chi Square 9.7, df=4, p=0.045).      
 
Table IV. Cross table of participants’ education and willingness to take part in the PES. 
 
Willingness SAT GCSE NVQ Apprentice A Level Graduate 
Post 
Graduate 
1 Not willing 36% (10) 29% (12) 36% (9) 40% (38) 36% (36) 37% (57) 45% (27) 
2 11% (3) 27% (11) 16% (4) 11% (10) 10% (10) 15% (24) 13% (8) 
3 Neutral 18% (5) 27% (11)  8% (2) 20% (19) 21% (21) 18% (28) 15% (9) 
4 14% (4) 12% (5) 28% (7) 17% (16) 26% (26) 17% (27) 8% (5) 
5 V. willing 21% (6) 5% (2) 12% (3) 12% (11) 8% (8) 13% (20) 18% (11) 
N 28 41 25 94 101 156 60 
Sample % 5.5% 8.1% 5% 18.6% 20% 30.9% 11.9% 
 
No relationship was found between a participants’ level of educational attainment and 
their reported level of willingness to take part in the PES. Model fitting information 
                                                          
9 A 5% significance level was used for all analyses unless otherwise stated  
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reported that education did not predict levels of willingness (Chi Square=1.94, df=6, 
p=0.925). 
Table V. Cross table of participants’ continent of origin and willingness to take part in 
the PES. 
Willingness Europe Asia & Africa America Australasia 
1 Not willing 41%  (102) 30% (8) 36% (66) 27% (13) 
2 15% (38) 22% (6) 13% (23) 6% (3) 
3 Neutral 18% (46) 22% (6) 18% (32) 23% (11) 
4 17% (42) 15% (4) 17% (31) 27% (13) 
5 Very willing 8% (21) 11% (3) 16% (29) 17% (8) 
N= 249 27 181 48 
Sample % 49.3% 5.4% 35.8% 9.5% 
 
Participants continent of origin significantly predicted their reported willingness to take 
part in the PES (Chi Square=8.3, df=3, p=0.034) with participants from Australasia 
being the most willing to take part in the PES.     
 
Table VI. Cross table of participants’ ethnicity and willingness to take part in a PES. 
Willingness White Mixed Asian Black Other 
1 Not willing 
38% 
(166) 30% (6) 40% (10) 33% (2) 28% (5) 
2 14% (59) 25% (5) 16% (4) 0% (0) 11% (2) 
3 Neutral 18% (80) 20% (4) 12% (3) 50% (3) 28% (5) 
4 19% (81) 10% (2) 20% (5) 0% (0) 11% (2) 
5 V. willing 11% (50) 15% (3) 12% (3) 17% (1) 22% (4) 
N= 436 20 25 6 18 
Sample % 86.3% 4% 5% 1.2% 3.6% 
 
No significant relationships were found between a participants’ ethnicity and their 
reported willingness to take part in the PES.   
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Table VII. Cross table of participants’ relationship status and willingness to take part in 
the PES. 
Willingness Single LT relationship 
Married, divorced 
or widowed 
1 Not at all willing 29% (67) 37% (53) 54% (69) 
2 14% (32) 17% (24) 11% (14) 
3 Neutral 22% (52) 22% (31) 9% (12) 
4 20% (47) 16% (23) 16% (20) 
5 Very willing 16% (37) 8% (12) 9% (12) 
N= 235 143 127 
Sample % 46.5% 28.3% 25.2% 
 
Participants’ relationship status was found to significantly predict their reported 
willingness to take part in the PES (Chi Square=20.8, df=2, p<0.001). Participants who 
were single were significantly more likely to report greater willingness to take part in 
the PES than people in long term relationships (beta estimate=0.921,df=1, p=0.000).  
 
Table VIII. Cross table of participants’ number of children and willingness to take part 
in a PES. 
Willingness 0 1 2 3+ 
1 Not willing 32% (155) 35% (13) 48% (28) 61% (33) 
2 15% (53) 16% (6) 12% (7) 7% (4) 
3 Neutral 22% (80) 8% (3) 14% (8) 7% (4) 
4 18% (64) 22% (8) 21% (12) 11% (6) 
5 Very willing 12% (44) 19% (7) 5% (3) 13% (7) 
N= 356 37 58 54 
Sample % 70.5% 7.3% 11.5% 10.7% 
 
The number of children a participant had significantly predicted their reported 
willingness to take part in the PES (Chi square=13.6, df=3, p=0.004). Participants with 
two or more children reported lower levels of willingness to take part in the PES, than 
people with one or no children. 
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Masculinity and willingness to participate in the PES 
Higher scores on the MQ were significantly related to greater reported willingness to 
participate in the PES (beta estimate=0.010, df=1, p=0.022). As individual variables 
using ordinal regression, MQ subscales physiological energy (beta estimate=0.046, 
df=1, p=0.01) and socio-cultural roles (beta estimate=0.027, df=1, p=0.008) 
significantly predicted participants’ level of reported willingness to take part in the PES. 
When both subscales were used in the ordinal regression model, socio-cultural roles 
remained a significant predictor of PES participation willingness 
(b=0.23,df=1,p=0.028), but physiological energy did not (b=0.034,df=1,p=0.063).  
 
The following subscales of the MQ were not statistically significant as predictors for 
participants’ willingness to take part in the PES; physical characteristics                     
(beta estimate =-0.002,df=1,p=0.942); idealised gender (b=0.012, df=1, p=0.498); 
sexual preference (b=0.012, df=1, p=0.498);subjective gender identity (b= 0.008, df=1, 
p=0.640); gender related age identity (b=0.017, df=1, p=0.436); gender related national 
identity (b=-0.023, df=1, p=0.173); lust (b=0.022,df=1,p=0.330); and male eroticism 
(b=0.018, df=1,p=0.362).  
 
Altruism and willingness to participate in PES   
Higher scores on the altruism scale were significantly associated with a greater degree 
of willingness to participate in the PES (beta estimate=0.24, df=1, p=0.002).   
 
Background analysis; demographics, masculinity and altruism  
Analysis of plotted distributions checked that predictor variables going into the ordinal 
regression were not too strongly associated with each other. Spearman’s rho was used to 
calculate the significance of correlations. Age was significantly correlated with 
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relationship status (r(505)=0.569, p<0.001) and number of children (r(505)=0.643, 
p<0.001). Number of children was also significantly correlated with relationship status 
(r(505)=0.580, p<0.001).   
 
Demographics, masculinity, altruism and willingness to participate in the reproductive 
health trial  
Demographic factors (age, continent, relationship status and number of children) and 
co-variables (altruism, masculine physiological energy and gender related socio-cultural 
roles), found to be significant predictors of willingness ratings, were analysed together 
using ordinal regression (Appendix 15). Table IX shows the beta estimates and p values 
for factors and variables.  
 
Table IX. Factor and co-variable ordinal regression output for dependent variable 
willingness to take part in PES.  
  Estimate Std. Error Wald df Sig. 
Physiological Energy 0.022 0.02 1.166 1 0.28 
Socio cultural roles 0.026 0.011 5.049 1 0.025* 
Altruism scale 0.03 0.009 10.836 1 0.001** 
[Children=0] 0.317 0.317 1 1 0.317 
[Children=1] 0.928 0.398 5.448 1 0.02* 
[Children=2+] 0a . . 0 . 
[Relationship= single] 0.675 0.306 4.861 1 0.027* 
[Relationship= long term] 0.29 0.302 0.918 1 0.338 
[Relationship= married]  0a . . 0 . 
[Continent=Asia & Africa] 0.014 0.386 0.001 1 0.97 
[Continent=Americas] 0.166 0.201 0.681 1 0.409 
[Continent=Australasia] 0.676 0.296 5.219 1 0.022* 
[Continent=Europe] 0a . . 0 . 
[Age=18-27] 0.601 0.275 4.758 1 0.029* 
[Age=28-37] 0.268 0.386 0.482 1 0.487 
[Age=38-47] 0.493 0.337 2.139 1 0.144 
[Age=47+] 0a . . 0 . 
*p<0.05 **p<0.01  
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MQ subscale socio-cultural roles and altruism remained significant positive predictors 
of reported willingness to take part in the PES. Demographic factors such as having one 
child, being single, being from Australasia, and being in the age group 18-27 also 
remained significantly positively related to willingness to take part in the PES.  
 
Masculinity and Altruism  
Spearman’s rho was used to analyse correlations between dimensions of masculinity 
and altruism (Appendix 16). Dimensions on the MQ of physical characteristics 
(r(461)=0.102, p=0.029), idealised gender (r(456)=0.131, p=0.005), subjective gender 
identity (r(451)=0.232, p<0.001) and lust (r(459)=-0.238, p<0.001) were significantly 
correlated to scores on the AQ at the 0.05 level. However, correlations between the 
dimensions of masculinity and altruism were all weak (r<0.25) and statistical 
significance may have been due to the sample size. The remaining dimensions of the 
MQ were not significantly correlated with scores on the AQ at the 0.05 level.   
 
Content Analysis Results 
Participants’ reasons for taking part in the PES are shown in table X. Helping and 
altruism were the most frequent reasons given by male participants to take part in the 
PES (n=145). Practical reasons (financial incentive, PES deemed not too burdensome) 
were the second most frequently stated reasons (n=84).  
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Table X. Qualitative comments about reasons FOR taking part in the PES.  
Reason Frequency 
(n=)  
Helping 145 
Altruism; helping science / helping fellow man 92 
Answering scientific questions (i.e. condom use, pregnancy, evidence)  36 
Good intentions of the study / worthwhile / legitimate study 17 
Practical  84 
Money 73 
Not too burdensome (i.e. travel, embarrassment)  10 
Anonymity 
 
1 
Interest 53 
Interest/ curiosity  31 
Funny / fun / enjoyable 12 
Experience / adventure 6 
Social discussion 3 
Relieve boredom  1 
Health 58 
Knowing sperm count 57 
Related health problems  1 
 
Participants’ reasons for not taking part in the PES are listed in table XI. Practical 
reasons (n=168) were the most frequent reasons given by participants for not taking part 
in the PES. Embarrassment (n=74) and privacy concerns (n=40) were the second and 
third most frequent reasons given.    
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Table XI. Qualitative comments about reasons for NOT taking part in the PES.  
Reason Frequency (N=) 
Practical 168 
Time constraints 64 
Inadequate financial incentive 34 
Travel distance 49 
Not enough study information 10 
Non drop in 4 
Partner refusal 7 
Embarrassment  74 
Embarrassment / Awkwardness 57 
Location (women & children department) 17 
Interest in PES 34 
Worthwhile research question 12 
No interest in study 22 
Health concerns 34 
Sperm count results refusal 7 
Vasectomy 23 
Age 4 
Privacy concerns 40 
Legitimacy of research 13 
Sample use concern 17 
Privacy concerns 10 
 
Table XII lists participants’ opinions of how masculine they perceived taking part in the 
PES would be. Over a third of responders to the question (n=43) believed that taking 
part in the PES had no bearing on their concept of masculinity. Over half of responders 
thought that the study was related to masculinity although responses varied from seeing 
participation as not at all masculine (n=27) to fairly / very masculine (n=32). Eight 
responders thought that taking part in the study was gender neutral and those who 
elaborated on their responses stated that different aspects of the study were perceived as 
either highly masculine or non masculine. For example, many responders suggested that 
‘helping others’ was seen as a non-masculine motivation, whereas overcoming 
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embarrassment and being assertive in taking part was described as a masculine 
behaviour.  
  
Table XII. Qualitative comments about how masculine or manly taking part the PES is 
perceived to be.  
Masculinity rating Frequency (n=) 
Not at all masculine (opposite of masculine) 27 
Fairly / very masculine 34 
Neutral* 8 
PES participation not related to masculinity 43 
No interest / Don’t know / Individual perception 13 
 
*Participants perceived aspects of the study as both highly masculine behaviours and 
not at all masculine behaviours (opposite of masculine).   
 
Discussion – Study 1 
The primary aim of study 1 was to examine what factors (demographics, altruism and 
masculinity) may predict a participant’s willingness to take part in a reproductive health 
trial (RHT). Secondly, the study aimed to explore whether men think masculinity or 
other individual factors may influence their willingness to take part in a RHT.  
 
Results replicated previous research indicating that men are generally unwilling to take 
part in RHTs (Muller, et al., 2004). Willingness ratings were also consistent with those 
of non-clinical respondents who are asked to enter clinical trials (Sanderson, in 
preparation). Analysis of the results suggested that men who were younger, single, had 
fewer children and were from Australasia, were more likely to take part in the PES than 
men from other demographic groups. Education and ethnicity did not influence men’s 
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willingness to participate in the PES in this study. Altruism was found to be a strong 
predictor of willingness to take part in the PES. When analysed as a co-variant with 
demographic factors and altruism, only the ‘socio-cultural roles’ dimension of the MQ 
remained a significant predictor of willingness to take part in the RHT. Dimensions of 
masculinity and altruism were shown to have low but significant correlations.  
 
Overall, the results were consistent with suggestions that potential participants employ a 
‘personal account balance’ when deciding to enter a RHT (Verheggen, Nieman, & 
Jonkers, 1998). Participants weigh up drivers and barriers to participation before 
deciding to enter a trial. The personal significance of these factors is influenced by 
participant’s background (Verheggen, Nieman, & Jonkers, 1998).  
 
Demographic factors 
Results showed that younger, single men with fewer children were more willing to take 
part in the PES. The findings replicated previous research which suggested that younger 
men are more willing (than older men) to take part in RHTs (Muller, et al., 2004) and 
clinical trials (Trauth, et al, 2000). The nature of the PES may have influenced 
differences between demographic groups. The PES advertisement (Appendix 13) 
discussed fertility and condom use. Younger, single men with fewer children are more 
likely to be concerned about fertility and family planning (than older, married men who 
already have a family) as intimacy and generativity are key stages in their present to 
near future psychosexual identity development (Erikson, 1968). Survey responders also 
suggested that interest or ‘no interest’ in the PES were drivers (n=31) and barriers 
(n=22) to participation. Knowing one’s sperm count (n=57) and answering questions 
about pregnancy and condom use (n=36) were quoted as reasons for participating in the 
PES. Men described how they would often be unwilling to take part in the RHT if they 
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already had children, if they were older, or had had a vasectomy. Sperm count results 
seem more important to younger men without children. This may be due to greater 
uncertainty about their fertility. In contrast, participants who are older, married or have 
had children, may be satisfied with their fertility or perceive RH as less of a priority.  
  
In contrast to previous research, ethnicity and educational attainment (Muller, et al., 
2004; Trauth, et al, 2000) did not seem to influence men’s willingness to take part in the 
PES. The recruitment of English speaking participants and problems generalising 
educational attainment across continents may have influenced these findings (see 
limitations).  
 
Interestingly, men from Australasia were much more willing to enter the PES than those 
from other continents. To date, there has been little research into regional differences of 
attitudes towards participation in clinical trials, let alone RHTs. The low number of 
participants (n=48) from Australasia in this study is also a limitation. Further research 
into regional differences of willingness to take part in clinical research trials is needed. 
Without further research, only speculation about possible factors underlying differences 
found in this study can be achieved. It may be that clinical trials in general are seen as 
more appealing in Australasian culture, or that people from Australasia have general 
trends in certain traits (i.e. altruism or lower levels of awkwardness) which influence 
their willingness to participate. Research Australia (2008) suggests that 68% of 
Australians would be willing to participate in clinical trials, a much higher percentage 
than the median willingness to participate in clinical trials (25-46%) found in a 
systematic literature review of non-clinical participants (Sanderson, in preparation).               
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Masculinity  
Results of this study suggested that overall masculinity did not influence RHT 
participation. Most dimensions of the MQ did not correlate with reported willingness to 
take part in the PES. Interestingly, 43 men also commented that participation in the PES 
did not relate to the concept of masculinity in any way. However, other men also 
perceived participating in the PES as a very masculine behaviour (n=34), or in contrast 
an emasculate behaviour (n=22). Men commented that the altruistic side of participation 
was emasculate, although the aspect of overcoming anxiety and embarrassment to take 
part was deemed a highly masculine behaviour. Comments are consistent with research 
into social constructions of masculinity; with courageousness and assertiveness 
constructed as a masculine behaviour (Golombok & Fivush, 1994). Taking part in 
health promoting behaviours is often seen as emasculate (Inhorn, 2004). Gender 
stereotypes often become widely shared beliefs about how men should act (Pleck, 
1987). It seems that the idea of participating in the PES may have caused a feeling of 
uncertainty or conflict in men’s self-construction of masculinity. Avoidance of this 
conflict could be one reason why the majority of males are unwilling to participate in 
RHTs.  
 
Questionnaire results also showed that men who saw traits such as assertiveness and 
dominance as desirable were more willing to take part in the PES. The dimension of 
Physiological Energy measured levels of testosterone by asking how desirable it is to be 
aggressive, assertive, competitive and dominant in society. A significant positive 
relationship between Physiological Energy and willingness to take part in the PES 
suggested that men who see traits associated with high levels of testosterone as 
desirable were more likely to take part in the PES. Greater willingness to participate in 
the PES may be because the value given to assertive and dominant behaviours 
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outweighed the negative value attached to helping or health promoting behaviours. 
However, this finding lost significance when demographic factors and co-variables were 
included in the analysis.  
 
Scores on the socio-cultural roles (SCR) dimension of the MQ remained a significant 
predictor of willingness ratings when analysed with demographic factors and co-
variables. SCR measured the roles (i.e. follow sports teams’ results, wear team colours) 
which men are expected to perform in order to be perceived as masculine within 
Western culture. Wearing a sports team’s colours and passionately following their 
team’s results may also suggest a willingness to be seen as part of a masculine group. 
SCR could have been a significant predictor of PES participation because similar to 
following a sports team, participating in the PES may have been constructed as a role 
that men should play to be part of a masculine group.   
 
The relationship between masculinity and willingness to take part in the PES 
contradicted the original hypothesis, that stated PES participation would be perceived as 
a ‘health promoting behaviour’ and a threat to masculinity (Courtenay, McCreary, & 
Merighi, 2002). Therefore, it was assumed that participants who perceived themselves 
as more masculine would be less willing to take part in the PES. Health promoting 
behaviours may be less of a threat to masculinity to younger men due to different cohort 
beliefs. Going to the doctors may no longer be viewed as such an emasculate behaviour 
for younger generations of men. This may explain why younger men were more willing 
than older men to take part in the PES. However, it may also have been that the PES 
was not perceived as a ‘health promoting behaviour’ or that there were other more 
salient aspects of the PES in relation to masculinity.  
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Altruism 
Altruism was found to be the most significant predictor of participation in the PES. This 
meant that men who have in the past helped strangers (i.e. push a car, give change) and 
organisations (i.e. donate blood, help charity) were much more likely to take part in the 
PES. Altruism was also quoted most frequently (n=92) as a reason for taking part in a 
clinical trial. Content analysis of participant’s comments found that ‘helping science’ 
and ‘helping a fellow man’ were the most frequent reasons given by participants in 
relation to helping. Altruism has previously been found to influence a participant’s 
willingness to take part in clinical trials (Trauth, et al, 2000; Kennedy & Burnett, 2007) 
and semen donation (Handelsman, Dunn, Conway, Boylan, & Jansen, 1985); hence, 
results are consistent with previous literature. The presence of truly altruistic behaviour 
has been questioned and it is possible that participants described altruistic reasons in an 
attempt to provide a ‘moral account’ of their actions (Healy, 2006). Participants’ 
concerns about how ‘important’ the PES was are consistent with Lawler and Thye’s 
(1999) social exchange theory, whereby people try to maximise the ratio of social 
rewards to social costs. Similar to the ‘personal account balance’ theory, if social 
rewards of the study (i.e. important research which leads to better lives for many) 
increase and costs decrease (i.e. less burden) then people are more likely to participate.   
 
Limitations  
Sample bias may have occurred as only men who chose to respond to the internet 
advertisement took part, excluding men without access to the internet. However, 
Gosling, Vazire, Srivastava & John (2004) report that internet samples are ‘relatively 
diverse demographically’ and ‘internet findings generalise across presentation formats, 
are not adversely affected by non-serious or repeat responders, and are consistent with 
findings from traditional methods’.     
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The advert aimed to be provocative to ensure recruitment of an adequate sample size. 
This included using a female model to advertise the survey online. However, this may 
have biased the sample of men who chose to take part, as men with a preference for 
females may be over-represented. Results from the MQ suggested that there were no 
significant differences in rating of willingness to take part in the PES, between men 
with a sexual preference for males or females.   
 
The study only measured willingness to participate and it is uncertain if this necessarily 
equates to behavioural participation. The study was unable to account for the difference 
between a stated intention (willingness) and behaviour (participation). Theory of 
reasoned action (TRA) (Ajzen and Fishbein, 1980) states that if a person intends to do 
something, then it is likely that they will do it. TRA suggests behavioural intention (BI) 
depends on a person’s attitude about the behaviour (A) and the influence of subjective 
norms (SN) (BI = A + SN). Subjective norms are the influence of one’s social 
environment on behaviour intentions. The study was unable to account for factors that 
occur between stating an intention and participation. For example, a participant may 
report high willingness to participate (attitude) on the survey and then discuss 
participation with their partner or friend, who describes negative views about 
participation (subjective norm). If the participant is influenced by the views of others, 
then they may then decide not to participate.  
 
The study recruited English-speaking people over the internet and included 256 men 
from outside of Europe. Survey choices for educational attainment may not have 
generalised to other countries. Recruitment from English speaking websites may have 
reduced ethnic diversity of participants as the majority of participants were white 
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(n=436).  Therefore, the findings of the study are only applicable to white western 
culture. 
 
There were also inherent problems with the construction and measurement of 
masculinity and altruism. The MQ and AQ enabled a large sample of men to quantify 
concepts of masculinity and altruism. Quantifying masculinity and altruism allowed 
hypotheses about their impact on willingness to take part in RHTs to be tested. 
However, masculinity and altruism are socially constructed (Moynihan, 1998) and 
therefore likely to differ between individuals and cultures. Although not the aim, the 
study was unable to measure if RHTs posed a threat to an individual’s masculinity. It 
may be that perceived threat to masculinity, as opposed to self-perceptions of 
masculinity, influence willingness to participate in RHTs.       
 
Further research  
Further research should aim to provide a more in depth and detailed understanding of 
how individual men construct, and attach meaning to, masculinity and altruism in 
relation to RHTs. This could include an exploration of a possible threat to masculinity 
posed by trial participation.  Although participants’ comments suggested that altruism, 
and to some degree masculinity, were drivers and barriers to PES participation, they did 
not explain these factors in detail. To date, there have been no published articles 
qualitatively exploring the reasons that influence participation in a male reproductive 
health trial. A qualitative methodology would allow for a much more in depth and 
detailed understanding of how individual men construct, and attach meaning to, 
masculinity and altruism in relation to RHTs.  
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Aim of study 2  
To qualitatively explore men’s reasons for participating in a RHT; to investigate the 
complex interactions between masculinity, altruism and RHT participation; to consider 
the individual experience of taking part in a RHT.      
 
Research questions 
1. What are the drivers and barriers to participation in a male RHT? 
2. What is the experience of men participating in a RHT?  
3. How does masculinity influence participation in a RHT? 
4. How does altruism influence participation in a RHT?   
 
Method 
Recruitment 
Participants were recruited from the online study conducted in study one. A detailed 
account of participant recruitment is described in the method of study one (pg 59). Of 
the 521 participants who filled out the online survey, 52 men left details to be contacted 
for an interview about their experience of taking part in a pre-ejaculatory fluid study 
(PES), conducted at a local IVF unit (Killick, Leary, Trussell, & Guthrie, In 
submission). Participants who left contact details suggesting that they resided out of the 
local area were excluded. Men were then selected in order of participation. Ten men 
were initially contacted; six confirmed that they had completed the PES; and five men 
agreed to be interviewed.  
 
Participants    
The five interviewees were aged between 22 and 25, with a mean age of 23. Four of the 
participants were university graduates and one was educated up to the age of 17. Three 
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of the men were in long-term relationships and two were single. None of the men 
reported having any children or health problems.     
 
Measures (Appendix 17)  
Questions on the interview schedule aimed to examine participants’ subjective drivers, 
barriers and experience of PES participation. Items on the schedule then assessed the 
influence of masculinity and altruism on PES participation, using dimensions of the 
Perceived Masculinity Scale (MQ: Chesebro & Fuse, 2001) as a framework. The 
interview schedule was reviewed and adjustments were made, following expert opinion 
from a Professor in the field of Obstetrics and Gynaecology at a local University, and 
members of the research staff team at the local In-Vitro Fertilisation (IVF) unit.  
 
Analysis procedure 
Interviews were transcribed then checked for accuracy against original recordings. 
Three out of five participants also checked their transcripts were a true representation, 
before they were anonymised. Once all interviews were completed, each interview was 
analysed individually. Analysis followed guidelines described by Smith, Flowers & 
Larkin (2009), presented in Figure II. Transcripts were read several times and notes 
were made in the left hand margin, next to extracts of interest. This procedure was also 
undertaken by a research supervisor (female, 3 transcripts), a local Professor in the field 
of Obstetrics and Gynaecology (male, 2 transcripts) and a Trainee Clinical Psychologist 
(female, 5 transcripts). The initial notes from each individual transcript were reviewed 
and emerging themes were recorded (Appendix 18). Male and female colleagues 
analysed transcripts in order to account for gender-influenced interpretations. Emerging 
themes were discussed between the researcher and co-analysts. This process was 
consistent with recommendations to make use of ‘supervision, collaboration, or audit to 
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help test and develop the coherence and plausibility of interpretation’ (Smith, Flowers 
& Larkin, pg 80, 2009).  A discussion of interpretations allowed for a deeper 
exploration of themes and endeavoured to use inter-rater comparisons to check validity 
of interpretations. Connections were then made between themes and transcripts. Two 
interviewees were consulted about developed themes for member validation. Super-
ordinate themes were compared across transcripts and included in the analysis if they 
occurred in over half the sample (table XIII).  
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Table XIII. Recurrence of super-ordinate themes across participants     
 
 
Results 
Three super-ordinate themes were evident in all of the participants’ transcripts (Table 
XIII).  
 
1.) A conflict in decision making; doing a ‘good thing’ versus the shame associated 
with a ‘socially frowned upon’ act 
 
Altruism 
Participants seemed to have conflicting views about the morality of taking part in the 
pre-ejaculatory fluid study (PES). Altruistic conceptualisations; such as doing 
something ‘good’ or helpful, were frequently given as reasons for taking part in the 
PES.  
 
Participant  Conflict in decision making; 
doing a ‘good thing’ versus the 
shame associated with a ‘socially 
frowned upon’ act 
Performance anxiety; 
‘less of a man’ 
Humour: coping 
strategies, stigma or 
the desire to be seen as 
cool in the face of 
adversity 
1 YES YES YES 
2 YES YES YES 
3 YES YES YES 
4 YES YES YES 
5 YES YES YES 
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 “The majority of people thought it was a good thing to be doing because 
obviously it’s for a good cause.” (P2).  
 “I feel proud of it because I think participating in anything where there is some 
positive gain in terms of health research, that’s fantastic.” (P3).  
“Just helping. I quite like, cos I don’t do much….I’d be more inclined and 
definitely think about it a lot more if I knew that I could be helping something.” 
(P1) 
 
Participants 1-3 described a moral element to their behaviour, suggesting they were 
‘proud’ to participate in research. Research in this study was experienced as a ‘good 
cause’ that could ‘help something’. However, all participants initially stated that they 
took part in the PES for ‘the money’ (expenses of £10 were given to participants by the 
department conducting the PES). Only later in the interview schedule did interviewees 
begin to describe the importance of altruism as a motivational factor for participating. 
Participants 1, 3 and 5 suggested that ‘helping behaviours’ are not seen as particularly 
masculine. Therefore, helping may not have been given as a reason to take part in the 
PES until the interviewee felt more relaxed with the researcher.        
 
“If in like my head I had an ideal masculine man I can’t imagine he went and did 
sexual reproductive studies. I don’t think it’s, no I just, the two don’t really go 
together in my head…thinking about an ideal masculine man, I always seem to 
think of like a lad’s lad, someone who doesn’t do, I wouldn’t say the opposite of 
that but someone who doesn’t really think about things like that and doesn’t, it’s 
not on their list of things to do.”  (P1). 
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“Influenced – I think if I wanted to be really, really masculine I probably wouldn’t 
have gone through with the study, don’t know for some reason it’s more 
masculine not to expect help.” (P5).  
“If you wanted to appeal to the sort of the less masculine side then you’d have to 
really promote the positive altruistic aspects of it” (P3). 
 
Interviewees may have given money as their primary reason as it fits with the masculine 
stereotype of a ‘breadwinner’ or ‘provider’. Words such as ‘task’, ‘job’ and ‘earned’ 
(P1-2) were used by interviewees to describe their experience of the PES. It may be that 
‘earning’ £10 (even though the £10 was advertised as ‘expenses’) was perceived as a 
socially acceptable reason, as a male, to give for taking part in the PES. In contrast, 
helping or being helped was not construed as a masculine behaviour, in relation to 
reproductive health. Intriguingly, the belief that helping by participating in RHTs is not 
a particularly masculine behaviour seemed to be in conflict with the threat to 
masculinity, associated with being seen as afraid or unwilling to take part.  
 
It’s not urgent… not like giving blood 
Interviewees suggested altruism was a driver for participation; although helping 
behaviours may not be seen as masculine and may not appeal to a ‘lad’s lad’ (highly 
masculine male). Despite altruism being given as a reason for taking part in the PES, it 
seemed that participation was not viewed as particularly important or urgent. For 
example, participant 1 described the difference in perceived importance between 
donating blood and giving semen for research:   
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“I think it’s not on the same level as giving blood for example but I do think that 
if something was found out to be important and it was an important discovery then 
yeah it could be but like I say people put more emphasis on other people who say 
give blood…obviously it’s needed for operations and things so there’s a lot more 
sort of urgency about give blood, keep people alive but you don’t have that sort 
of, give semen, find out whether pre-cum contains sperm, like there’s not, it’s sort 
of an urgency or something like that.” (P1).  
 
Perceptions that PES participation is not important are likely to reduce men’s 
willingness to enter the study. Reproductive health problems seemed not to be thought 
about, or talked about, in this sample of men. Interviewees also seemed to have very 
little empathy for people with reproductive health problems and research into RH did 
not seem to be thought about. It may be that men do not talk about RH problems, due to 
stigma associated with masturbation, or having a reproductive health problem.  
 
Interestingly, when interviewee’s perceived that participation was more urgent or 
important, they were more willing to take part in the PES. For example, participants 1 
and 3 described how they were more willing to take part in the PES as they were ‘close 
to the subject’ or it was ‘suggested by somebody they knew’. When participants viewed 
their involvement in the study as not only helpful but needed, for example if there was a 
‘shortage of white males’, they seemed much more willing to take part:  
 
“The fact that it was suggested by someone I knew then that probably influenced 
me more so I would think but it being a good deed was definitely a part.” (P1). 
“If there was a shortage of white males taking part then I think then it would have 
affected (decision to take part)” (P1).  
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“I think I wouldn’t have taken part in this one had I not have been, I don’t know 
so close to the sort of subject if that makes any sense but I, due to the fact that it 
wasn’t well explained, I wouldn’t just jump in and do another one.” (P3).  
 
‘Socially frowned upon’ 
The moral justification for taking part in the PES appeared to be in conflict with the 
stigma attributed to the act of masturbation, required for the PES.  
 
“People who I’ve spoken to about it, some people have been almost prudish about 
it which I don’t understand because it’s not like you were just doing it in public, it 
was for an experiment in a medical facility so it wasn’t anything disgusting about 
it….they just found it all a bit bizarre” (P2) 
“I think obviously the embarrassment factor and what they think other people will 
think of them for doing it and what they think the process is like” (P5) 
“I certainly perceived people looking at me and wondering why I was there but I 
suppose really getting down to it, it’s the potentially slightly socially on the face 
of it, socially frowned upon masturbation activity that was required and yeah 
there’s still some social or cultural taboo about that.” (P3)  
“I think I could have definitely done something else I would have rather done than 
that to satisfy myself but yeah that was due to all of the build up the anxiety and 
the nervousness.” (P1)  
 
Other people’s perceptions of the PES were described as ‘bizarre’, ‘disgusting’, 
‘socially frowned upon’ and ‘taboo’. It is likely that other people’s beliefs influenced or 
even reflected participants own thinking about the PES. Positive aspects of helping 
science seemed to conflict with stigma associated with masturbation. Participant 2 
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seemed to dispute negative perceptions about the PES, giving a moral explanation how 
it was for an ‘experiment in a medical facility’. His account seemed to be an attempt to 
persuade himself, as well as the interviewer, of the moral reasons for participation. The 
extract portrays the ambivalence of feelings towards the PES, from feeling proud of 
participating in medical research to feeling ashamed in relation to stigma associated 
with masturbation. It seems that similar to financial rewards and helping behaviours, 
stigma associated with the PES influenced the decision making process. Once the 
individual had taken part in the PES, participants began a process of rationalising their 
behaviour, to give a moral account of their actions. This can also been seen in the 
extract from participant 1, suggesting that he ‘could have definitely done something else 
he would have rather done’. Due to the shame associated with masturbation in hospital, 
it seems that accounts were given to distance themselves from the perceived ‘deviant’ 
position of enjoying PES participation. Instead, the study was conceptualised as a ‘task’ 
that ‘needed to be done’ (P2).  
 
Masturbation is not talked about and semen is a ‘waste product’ 
Participant 3 described how masturbation is not discussed in his culture and semen was 
conceptualised as a ‘waste product’, which would normally be cleared up and hidden: 
 
“You don’t go and talk about your masturbation success with your male mates at 
the park and you wouldn’t do it with females either. It’s still an individual thing so 
all this gender is irrelevant to some extent…  
The fact that that’s the taboo thing to do and you’ve done it in a hospital and then 
you’re presenting the contents of that which again as a waste product, there’s a 
taboo about that as well so there might be something about that there as well that 
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you know, here’s something you’d usually clean up you know, to have any 
evidence of and you’re presenting it all to someone.” (P3). 
 
It is interesting that semen is described almost shamefully as a ‘waste product’. This is 
in contradiction to the view of medical researchers, who value donations of semen and 
describe how research into ejaculatory fluid is often under resourced. The shame 
associated with masturbation seems to be an important factor in the avoidance of talking 
about, and taking part in, reproductive health research.  
  
2.) Performance anxiety; feeling ‘less of a man’  
The importance of masculinity  
Initially, interviewees’ did not consciously link participation in the PES with their 
concept of masculinity. As interviews progressed, the relationship between masculinity 
and the PES became more apparent. It may be that participants in the study did not have 
a clear concept of what masculinity meant to them. Although descriptions of the 
meaning of masculinity seemed difficult to verbalise, interviewees’ acknowledged that 
it was important for them to be seen as masculine.  
 
 “I think probably I wouldn’t like to say but obviously consciously I would have 
said being male and probably like most males like yeah it’s important, sorts the 
social pecking orders that are just like formed naturally but like obviously it’s 
important to everyone, nobody wants to be at the bottom of that pecking order do 
they?” (P4)  
“I’d say it’s quite important. I like to be seen as masculine particularly with a 
female. You want to be seen as masculine. You don’t want to, I don’t want to be 
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like an alpha male sort of thing that you get with some people but I like to be quite 
masculine.” (P5) 
 
Masculinity appeared to be important for participants in relationships with both 
genders, although interviewees preferred to be seen somewhere in the middle of a 
continuum of masculinity. Being ‘masculine’ seemed important in relation to social 
dominance (‘pecking order’) with other men. Participant 5 described the importance 
of being seen as masculine with females, suggesting the perceived desirability of 
masculine traits in sexual situations.    
 
Catastrophic predictions  
As described earlier, interviewed men described the PES as a ‘job’, ‘task’ or something 
that ‘needed to be done’. They also described a level of anxiety, or ‘stage fight’ (P2), 
about taking part in the PES: 
 
 “But it was just the whole, the build up to it, the banter, the going through in your 
head what you’re thinking, you get yourself a bit het up sometimes if you don’t 
know what to expect. Like I say, once I was there I was fine.” (P2). 
 “About the unknown… how the sample was going to be taken. Obviously you 
think of sort of sexual tests for things like STDs that doesn’t make you think 
happy thoughts so if it was anything like that I would have been put off and 
probably wouldn’t have actually done the tests, if it was anything to do with a 
swab I was going to leave. …. If I’d have known then it would have been a lot 
less nerve racking I think.” (P1).  
 
 
 
95 
 
Interviewees suggested they were initially anxious about what the PES entailed and 
described a fear of the ‘unknown’. Uncertainty about trial procedures seemed to cause 
catastrophic predictions. Participant 1 appeared to base his predictions on previous 
negative experiences of sexual health clinics; including fearful thoughts about medical 
testing and the use of ‘swabs’. It is interesting how interviewees associated the PES 
with the stigmatised area of sexually transmitted disease (STDs). Catastrophic 
predictions, resulting from an uncertainty about the PES procedures, are likely to be a 
barrier to participation.  
 
Exposure: modification of catastrophic thoughts 
Once participants had taken part in the PES, they reported a much greater willingness to 
take part in future RHTs. The experience of participation seemed to modify beliefs 
about RHTs and resulted in participants’ feeling more relaxed about the procedure.   
 
 “It was a lot easier than I thought – a lot more relaxed than I was expecting. I 
wouldn’t call it a pleasurable experience but I would probably do it again.” (P1).  
“You never know what it’s going to be like until you’ve tried something. Now 
I’ve done it I’d quite happily do a study like that again.” (P2).   
“I’m more willing to do it now that I’ve actually done it. I just don’t know what I 
was getting embarrassed about to be honest. It was fine.” (P3).   
 
Participants 1-3 described feelings ‘fine’, ‘relaxed’ and ‘happy to do it again’. It may 
be that interviewees have tried to minimise their feelings of anxiety, as being viewed 
as fearful or anxious may not be seen as socially acceptable for a male in this 
situation.  
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The ‘lad mentality’ versus the ‘inadequacy’ in failure   
Desires to be seen as ‘one of the lads’ by being courageous and taking part in the PES, 
seemed to conflict with a fear of ‘failing to perform’.  
 
“Probably just the way I perceive myself like I suppose it’s part of the ‘lad’ 
mentality isn’t it, one of the lads and you don’t want to be one of the people that 
doesn’t do something or can’t do something.” (P2).  
“There’s a lot of pressure at the time you feel because you’re in this very strange 
environment and you’re, it’s, you’re doing this as a means to an end for a 
study…you don’t want that setting or that peculiarity being able to beat you being 
able to do it because the activity usually requires you to be relaxed and 
comfortable so in that respect I suppose it’s a challenge to your ability to do that 
and maybe that’s a challenge to your masculinity. It is an assessment of whether 
you can produce this, conduct this activity.” (P3). 
“Failure to perform, something like that. That would have been 
embarrassing……Just the fact that I knew the people that I was going with. There 
was more than one of us there…actually embarrassing even with someone you’ve 
never met like the woman. If I came out it was like… 
Researcher: About not being able to perform... What would that mean? 
Inadequacy… yeah less of a man.” (P1) 
 
Interviewees described a social pressure to be able to ‘perform’ in the situation. Words 
such as ‘assessment’, ‘challenge’ and being ‘beaten’ conveyed a perception that the PES 
was testing their masculinity.  A failure to ‘perform’ in the study connected to feelings 
of ‘inadequacy’ and a threat to masculinity. Participant 3 explained that anxiety about 
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being able to produce a semen sample, in a strange setting, was perpetuated by a 
perceived need to be relaxed in order to ‘perform’.  
 
Social comparison and expectations versus the need for peer support 
Interviewees’ responses encapsulated a powerful theme of social comparison. They 
described not wanting to ‘be the one that can’t do it’ and conveyed a sense of 
embarrassment and inadequacy if that were the case.    
 
“I didn’t know how long I should really be in there. I remember two people before 
me sort of for ages and I was like well, I could finish this experiment in two 
minutes and I didn’t know about being strange or this or that so I purposely hung 
on for a bit longer.” (P5) 
“I was thinking if I get stage fright and can’t perform then I’ll feel a bit stupid 
telling people. I think I would have felt a little bit, like it was testing my 
masculinity if I couldn’t have done it.” (P2) 
“If there were three people or if it was a larger group together then it would be 
sort of, the pressure of just being around your friends, not necessarily the 
embarrassment but the whole uncomfortableness.” (P1) 
 
Participants 1, 2 and 5 described feeling ‘embarrassed’, ‘uncomfortable’ and ‘stupid’ 
when taking part with their friends. These feelings appeared to relate to a threat to their 
masculinity, or an uncertainty about being seen as ‘normal’ in this situation. The desire 
to be seen as masculine is apparent when participant 5 described how he ‘hung on for a 
bit longer’ in order to be seen as the same as the other participants. 
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However, a strong desire to conduct the PES with other people was also described by 
interviewees. Being in a group may have helped to manage the feelings of shame, which 
participants associated with the stigma of participation. Peer support and humour, as 
discussed later, may also have provided a method of coping with the uncomfortable 
feelings described by interviewees. However, knowing other men that were 
participating also seems to have put pressure on interviewees to take part themselves. 
 
“I wouldn’t have gone had I not have been with the people went with. I also don’t 
think I would have gone on my own. I think if it wasn’t a social thing, it’s, if we 
hadn’t have made it into a social thing, I don’t think I would have done it. It was 
almost that I had to do it with a group. I wouldn’t do it on my own.” (P1) 
“I think if I didn’t know other people were doing it, I wouldn’t have been the first 
person to say yes, that’s the only thing really…It’s the way people perceive me; I 
didn’t want to be seen as not wanting to do it... I was quite interested in how it 
works but then again my ego wouldn’t let me not do it when somebody else was 
doing it.” (P2)  
 
Participant 2 described how his ‘ego wouldn’t let him not do it when somebody else was 
doing it’. Although helping RHTs was not seen as a masculine behaviour, being seen as 
unable, or not wanting to participate because of fear or embarrassment, was seen as a 
much greater threat to masculinity.         
 
Healthy sperm and masculinity 
The PES researchers gave participants the choice to find out details about their ‘sperm 
count’.  
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“It’s something like me personally I’ve never really thought about so yeah it’s 
kind of like everything, it’s kind of rushing into your mind at once, a ‘what if’ 
question, do you know what I mean? So yeah for about five minutes you do feel 
I’ve never actually thought about this is and it’s quite, you can measure it by your 
relief.” (P4).  
“Erm, potentially just with the desire to know whether my sperm’s healthy and 
everything because I think that’s linked with masculinity and I think I obviously 
wanna know that just in case. That’s a by-product of the test obviously being able 
to find that out. But yeah that’s come at an age where if there is something wrong, 
I can see someone and start doing something about it so yeah, I think in that sense 
affected me… Probably just going back to the actual like healthiness of the sperm, 
that’s the only reason cos obviously I don’t want to be impotent or anything like 
that” (P1).  
 
Participant 4 suggested that he had not previously thought about the topic. When given 
the choice to find out his results, he described a ‘rush’ of anxious thoughts and 
predictions. The ‘healthiness’ of sperm was associated with the concept of masculinity 
for participant 1. It seems that sub fertility was experienced as a serious threat to 
masculinity for some interviewees and was reflected by participants’ experience of 
relief on finding out they were fertile.  
 
3.) Humour and coping     
Difficult feelings associated with participating in the PES, such as shame, 
embarrassment, anxiety, fear and inadequacy, were described by interviewees. 
However, all interviewees described their experience of the PES as being much easier 
than expected. Extracts from interviewees’ transcripts indicated how some difficult 
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feelings were managed. Humour seemed to be a prominent coping strategy used across 
participants. 
 
“…a bit nerve racking on the way there, kind of had to keep cracking jokes about 
it as I was really nervous.” (P2) 
“Everyone I’ve spoken to seems to think it’s a bit of a joke as in you’re doing it 
for a laugh, not necessarily, there is medical reason behind it obviously but my 
peers see it as something a bit of fun to do, they don’t see it as masculine or 
anything like that.” (P1) 
“I think by response with speaking to people after or about it, I think there is quite 
a bit of like interest like humour brought towards it and I think that’s probably due 
to obviously the situation and what you’re actually have to do in the test.” (P4) 
 
‘Cracking jokes’ may have helped to reduce the tension and anxiety associated with 
participation. However, humour may also have been employed as a method of 
communicating distance from the stigma they associated with participation in the 
PES. Making jokes about the PES may also have been a way for participants to 
demonstrate that they did not take the situation too seriously. It seemed that 
interviewees did not want to be perceived as having fears or difficulties regarding 
RH. It may be that men minimised the emotional impact participation in the PES had 
on them. For example, participant 5 repeated ‘no’ or ‘not’ five times, in response to a 
question asking about feeling fearful in relation to PES participation.  
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Researcher: Did you have a fear of failure? 
“No. No, not, no, not before and during you potentially you realise that you’re not 
as comfortable as you’d normally be so that might be an issue but no I didn’t 
worry about that.” (P5).  
 “Knowing that I would, I don’t have difficulties or any sort of feeling 
uncomfortable affecting whether I can produce what was required for the study 
meant that because I knew I could rely on myself in that situation, it would be 
reasonable for me to do it so yeah it’s more about just knowing that there wasn’t 
uncertainty in me in my own performance in that situation.” (P3). 
  
Humour may help to portray the message to others that ‘I’m not really interested in 
helping’, ‘I think this is bizarre too’ or ‘I’m not afraid, I’m having a laugh’. 
Therefore, humour may be exercised in various ways to cope with difficult feelings 
associated with stigma and a threat to masculinity.  
 
Analysis of interviewee’s transcripts also suggested that men used other strategies to 
cope with difficult feelings associated with participation. Interviewees described 
experiencing feelings of anxiety stemming from uncertainty about the study 
procedure. It may be that interviewees’ own anxieties, arising from an underlying 
threat to their masculinity, were projected onto the PES procedure. Parts of 
interviewees’ responses also appeared to rationalise their behaviour. Although this 
often provided a detailed account of their experience, it seemed devoid of emotional 
content. Therefore, interviewees may have intellectualised conversations in an 
attempt to cope with, or avoid, feeling difficult emotions. There also seemed to be 
evidence that participants avoided difficult issues.  
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“I remembered one of the cups wouldn’t shut properly or wouldn’t seal properly 
so I’d sort of kept it a certain way in the bag so it wouldn’t get spilled. I had to 
sort of get that message across to the female who had shown me into the room and 
I certainly felt a bit awkward doing that because I think at that stage, there’s very 
little eye contact, it’s just the case of getting the sample and giving the sample 
over and getting out and I think they know that as much as you do so they’re 
equally happy to make the transaction as quick as possible.” (P3).  
 
Participant 3 describes an attempt to avoid talking about an ‘awkward’ issue with a 
female researcher. This extract illustrates the use of avoidance to cope with 
potentially overwhelming difficult feelings. Low levels of male participation may 
therefore result from men’s use of avoidance, to cope with the difficult feelings 
associated with participation in RHTs.  
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Table XIV. Super-ordinate themes and associated sub themes.             
 
  
Super-ordinate themes and associated sub themes 
A conflict in decision making; doing a ‘good thing’ versus the shame associated with a 
‘socially frowned upon’ act 
• Altruism 
• It’s not urgent… not like giving blood 
• ‘Socially frowned upon’ 
Performance anxiety; feeling less of a man 
• Importance of masculinity 
• Catastrophic predictions and exposure 
• ‘Lad mentality’ versus ‘inadequacy’ in failure 
• Social comparisons and peer support 
• Healthy sperm and masculinity 
Humour and coping 
• Humour 
• Avoidance, projection, minimisation and intellectualisation  
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Discussion – study 2 
Overview of findings 
An interpretative phenomenological analysis of interviews with men about their 
experience of RHTs led to the development of three core themes. Stigma associated 
with masturbation and RH problems were experienced as barriers to RHT participation. 
Catastrophic predictions about the trial procedure, ‘performance anxiety’ and an 
underlying threat to masculinity associated with feelings of ‘inadequacy’ were also 
interpreted as barriers to RHT participation. In contrast, a desire to undertake a helping 
behaviour, to be ‘one of the lads’ and step up to the challenge, seemed to be drivers to 
RHT participation. Humour was the most frequently used coping strategy in this 
sample, although intellectualisation, avoidance and projection were also interpreted as 
strategies for coping with feelings of shame, anxiety and embarrassment.  
 
Decision making model 
Interviewees’ decisions to take part in the PES appeared to be based on a cognitive 
appraisal of the pros and cons of participation. The perceived importance of individual 
drivers and barriers to participation seemed to vary, depending on how individual 
participants experienced them. The adapted Health Belief Model (Verheggen, Nieman, 
& Jonkers, 1998) suggests that potential participants have a ‘personal balance account’ 
to assess before consenting to take part in a clinical trial. Similar to accounts from 
interviewees in this study, Verheggen, et al, (1998) suggests the decision to take part in 
a trial is calculated by the physical and emotional value that the participant hopes to 
gain from participation, compared to non participation, minus the expected risks and 
extra time expected from trial participation. The model also suggests that background 
factors, beliefs, locus of control, attitudes, expectations and perceptions have an inter-
related influence on the decision to participate in a trial.  
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Stigma of masturbation and reproductive health  
Historically, masturbation has been viewed as a ‘moral sin’ by various religions, 
including Judaism, Islam and Christianity. Interviewees in this study experienced 
masturbation as a socially ‘taboo act’ and reported feeling embarrassed about taking 
part in the PES. These reports are endorsed by Coleman (2002), who suggests that 
masturbation tends not to be openly talked about and negative attitudes persist. Feelings 
of embarrassment and awkwardness have been elicited in previous qualitative research 
into masturbation (Spencer, Faulkner, & Keegan, 1988). Embarrassment or 
awkwardness was reported as the second most frequent barrier to PES participation 
(after practical reasons) by participants in study one.  
 
Interviewees’ in study two suggested that perceived stigma associated with entering the 
PES was less significant when participating in a group. It may be that men used other 
males as references for appropriate behaviour. Wade (1998) describes ‘reference group 
dependent’ males being characterised by psychological relatedness to some males and 
not others. Feeling socially connected with other males (if social aspects of identity are 
important for the individual) may help to overcome feelings of shame associated with 
RHT participation. It may be that when men observe other men (who they feel 
psychologically related to) enter a RHT, they are reassured that participation is ‘normal’ 
and the perceived stigma is reduced or shared.      
 
Altruism 
‘Doing a good thing’ was described by participants as an important reason to take part 
in the PES trial. Altruism was also the most frequent reason given for PES participation 
by 505 in an internet survey (study one) and a significant reason to take part in clinical 
trials for ‘healthy’ people (Sanderson, in preparation). Suggesting that altruism was the 
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primary motivation for trial participation might have been a way for the men to 
rationalise their own behaviour and to communicate a moral character to others. People 
are much more likely to undertake a voluntary endeavour if they can provide a ‘moral 
account’ of their actions (Healy, 2006). Financial incentives described by interviewees 
at the beginning of interviews may also have reflected an attempt to provide a rationale 
for their actions. However, interviewees accounts of a sense of pride, or ‘feeling good 
about taking part in the trial, were consistent with findings that people often enjoy the 
benefit of a ‘warm glow’ when conducting a helping behaviour (Andreoni, 1990). 
Altruistic motivations increased when interviewees viewed participation as more urgent 
or individually relevant. Participants may have been more likely to take part in the PES 
as low participation rates and the need for men to give their opinion, were 
communicated in the rationale for the survey. The findings are consistent with the social 
psychology theory of the bystander effect; where the greater the number of bystanders 
who witness an event, the less likely any one of them is to help (Latane & Darley, 
1970). When men viewed themselves as individually ‘needed’ or more vital to the 
success of the study, they may have been more willing to take part.     
 
Similar to findings from study one, there seemed to be some ambivalence regarding 
altruism and masculinity. Helping behaviours and concerns about reproductive health 
were constructed as emasculate, as reported elsewhere (Courtenay, 2000). In contrast, 
being ‘one of the lads’ and stepping up to take part was constructed as a masculine 
behaviour. Although some participants in this study reported that being seen as 
‘masculine’ was important to them, none of the participants described themselves as 
extremely masculine. Therefore, taking part in a helping behaviour such as the PES may 
not have resulted in the cognitive dissonance possibly experienced by ‘extremely 
masculine’ men.  
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 Anxiety and a threat to masculinity 
Experiences of PES participation can be mapped onto a traditional cognitive 
behavioural model of anxiety (Westbrook, Kennerly, & Kirk, 2007). Interviewees 
described catastrophic predictions, and anxious feelings, about the PES procedure. A 
review of published literature suggests that uncertainty about trial procedures are a 
common barrier to participation for patients groups and non-clinical samples (Ross, 
Grant, Counsell, Gillespie, Russell, & Prescott, 1999; Sanderson, in preparation). 
Negative predictions are rarely challenged as men continue to avoid participating in 
RHTs. However, when men do take part in a RHT, as in this study, catastrophic 
predictions are modified and anxiety reduces. Catastrophic predictions seemed to be 
triggered by an uncertainty about the trial procedure, with participants reporting beliefs 
that the procedure would be intrusive, medical and socially awkward. It also seems that 
underlying the feelings of anxiety was a threat to participants’ masculinity, and a sense 
of inadequacy. Inhorn (2004) suggests that sub fertility and erectile dysfunction are seen 
as particularly emasculating. A fear of ‘failure’ and the resulting anxiety seemed to 
influence the participants’ perceived ability to ‘perform’, therefore becoming a vicious 
cycle.             
 
Limitations and future research 
Due to the retrospective nature of the study, men’s accounts of RHTs were likely to be 
influenced by their experience of the PES. Although this allowed for a detailed account 
of experience of PES participation, it is uncertain if these findings can be generalised to 
other RHTs, or to men who have not taken part in a RHT. Due to the culture-specific 
and idiosyncratic meanings of masculinity and altruism, definitions of these concepts 
were not provided to participants. Therefore, participants explored their own 
experiences and meanings of the PES, masculinity and altruism. Although consistent 
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themes were found across participants in this study, further research with a varied 
sample of male participants, on different RHTs, is needed.        
 
Recommendations from study 1 and 2 
Recommendations for future RHT recruitment strategies can be made from the results 
of study one and two. Altruism was a significant predictor and most frequent reason for 
PES participation, given by participants in study 1. Future clinical trials could 
emphasise the altruistic elements of participation in recruitment. Psychological literature 
on increasing altruistic behaviours could guide recruitment strategies. For example, 
highlighting psychological concepts (such as the bystander effect) that serve as barriers 
to helping behaviours have been shown to increase the behaviour (Beaman, Barnes, 
Klentz, & McQuirk, 1978). Recruitment advertisements could stress the importance of 
the individual to the outcome of the trial and give men an opportunity to feel proud of 
undertaking a worthwhile cause, or to display their ‘moral character’. Promoting the 
benefits of participation, increasing empathy for the purpose of RHTs, and highlighting 
the importance of each individual to the outcome, are likely to increase men’s altruistic 
tendencies (Bateson, 1991). However, careful consideration should be given to ensure 
that participation is perceived more as an ‘important moral act’ than an ‘emasculate 
concern about one’s own health’.  
 
Overall, participants in both studies did not seem to think that masculinity affected their 
willingness to take part in the PES. However, the dimension of social and cultural roles 
remained a significant predictor of PES participation. Expectations of men to conform 
to socio-cultural roles and the use of other men’s behaviour as a guide or reference 
could aid recruitment. Future recruitment strategies could target groups of men, such as 
sports teams or societies, to establish confidence that participation is socially accepted.  
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Participants’ interests influence their willingness to enter a RHT and differences 
between demographic groups may be due to different interests. For example, younger 
males with fewer children in this study may have been more willing to enter the PES 
due to interest in fertility and conception. Therefore, tailoring trial recruitment 
advertisements to specific demographic groups may improve recruitment rates. 
Recruitment may also be improved by changing the practice of RHTs; such as providing 
more detailed information about the process and rationale of a trial, moving location 
away from the ‘women’s and children’ hospital’, allowing more flexible drop in times, 
increasing financial incentives and providing travel expenses. 
 
Stigma about masturbation and RH in general was found to be a key reason not to 
participate in the PES. By challenging beliefs about stigma associated with RHTs, or 
facilitating methods of coping or overcoming stigma, it is likely that more males will 
consider participation. Such methods could include moving trials, if appropriate, to 
more accessible geographical and service locations, as mentioned above. Exposure to 
RHTs through videos or information centres, at neutral venues, may also help to reduce 
stigma.  
  
Recruiting men in groups and informing them more about the procedure, may also help 
to reduce negative predictions about RHTs. For example, specific explanations could be 
given about the type of procedure, to provide reassurance about privacy, and where 
applicable dispelling myths about invasive medical procedures. Facilitating popular 
coping strategies, such as humour and peer support, should also help participants to 
manage feelings such as anxiety and awkwardness. It is for future RHT conductors to 
assess the effectiveness of these recommendations.     
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Conclusion   
Study 1 tested the relationship between masculinity, altruism and reproductive health 
trial participation. Altruism, but not masculinity, significantly predicted a man’s 
willingness to enter a trial. Study 1 was limited by a quantitative design and the 
complex relationships between masculinity, altruism and RHT participation could not 
be fully explored. 
 
Study 2 provided an interpretative phenomenological analysis of men’s responses to a 
semi-structured interview, about the experience of taking part in a reproductive health 
trial. Three super-ordinate themes were developed, including; a conflict in decision 
making between doing a worthwhile act and the perceived stigma associated with 
openly discussing and participating in reproductive health trials; the anxiety associated 
with ‘performing’ for a trial and a threat to masculinity; and humour and coping 
strategies to help manage awkward situations. Findings were discussed in relation to 
previous literature and recommendations to future researchers are made.     
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Appendix 1 
Guidelines for authors for the journal ‘Trials’  
There is no explicit limit on the length of articles submitted, but authors are encouraged 
to be concise. There is no restriction on the number of figures, tables or additional files 
that can be included with each article online. Figures and tables should be sequentially 
referenced. Authors should include all relevant supporting data with each article.  
Review articles 
Review articles are summaries of recent insights in specific research areas within the 
scope of Trials. Key aims of reviews are to provide systematic and substantial coverage 
of mature subjects, evaluations of progress in specified areas, and/or critical 
assessments of emerging technologies. 
Manuscript sections for Review articles  
 
Manuscripts for Review articles should be divided into the following sections: 
• Title page 
• Abstract 
• Review 
• Conclusions 
• List of abbreviations used (if any) 
• Competing interests 
• Authors’ contributions 
• Acknowledgements 
• References 
• Figure legends (if any) – see Figure legends section in main document 
• Tables and captions (if any) – see Tables section in main document 
• Description of additional data files (if any) – see Additional files section in main 
document 
Title page  
 
This should list the title of the article, the full names, institutional addresses, and email 
addresses for all authors. The corresponding author should also be indicated. 
Abstract  
 
This should not exceed 350 words. Please do not use abbreviations or cite references in 
the abstract. 
Review  
 
This should contain the body of the article, and may also be broken into subsections 
with short, informative headings. 
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Conclusions  
 
This should state clearly the main conclusions of the Review and give a clear 
explanation of their importance and relevance. 
List of abbreviations  
 
If abbreviations are used in the text, either they should be defined in the text where first 
used, or a list of abbreviations can be provided, which should precede the competing 
interests and authors’ contributions. 
Competing interests  
 
A competing interest exists when your interpretation of data or presentation of 
information may be influenced by your personal or financial relationship with other 
people or organizations. Authors should disclose any financial competing interests but 
also any non-financial competing interests that may cause them embarrassment were 
they to become public after the publication of the manuscript. 
Non-financial competing interests 
Are there any non-financial competing interests (political, personal, religious, 
ideological, academic, intellectual, commercial or any other) to declare in relation to 
this manuscript? If so, please specify. 
If you are unsure as to whether you or one of your co-authors has a competing interest, 
please discuss it with the editorial office. 
Authors’ contributions  
 
In order to give appropriate credit to each author of a paper, the individual contributions 
of authors to the manuscript should be specified in this section. 
An “author” is generally considered to be someone who has made substantive 
intellectual contributions to a published study. To qualify as an author one should 1) 
have made substantial contributions to conception and design, or acquisition of data, or 
analysis and interpretation of data; 2) have been involved in drafting the manuscript or 
revising it critically for important intellectual content; and 3) have given final approval 
of the version to be published. Each author should have participated sufficiently in the 
work to take public responsibility for appropriate portions of the content. Acquisition of 
funding, collection of data, or general supervision of the research group, alone, does not 
justify authorship. 
We suggest the following kind of format (please use initials to refer to each author’s 
contribution): AB carried out the molecular genetic studies, participated in the sequence 
alignment and drafted the manuscript. JY carried out the immunoassays. MT 
participated in the sequence alignment. ES participated in the design of the study and 
performed the statistical analysis. FG conceived of the study, and participated in its 
design and coordination and helped to draft the manuscript. All authors read and 
approved the final manuscript. 
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All contributors who do not meet the criteria for authorship should be listed in an 
acknowledgements section. Examples of those who might be acknowledged include a 
person who provided purely technical help, writing assistance, or a department chair 
who provided only general support. 
Authors’ information  
 
You may choose to use this section to include any relevant information about the 
author(s) that may aid the reader’s interpretation of the article, and understand the 
standpoint of the author(s). This may include details about the authors’ qualifications, 
current positions they hold at institutions or societies, or any other relevant background 
information. Please refer to authors using their initials. Note this section should not be 
used to describe any competing interests. 
Acknowledgements  
 
Please acknowledge anyone who contributed towards the study by making substantial 
contributions to conception, design, acquisition of data, or analysis and interpretation of 
data, or who was involved in drafting the manuscript or revising it critically for 
important intellectual content, but who does not meet the criteria for authorship. Please 
also include their source(s) of funding. Please also acknowledge anyone who 
contributed materials essential for the study. 
The role of a medical writer must be included in the acknowledgements section, 
including their source(s) of funding. 
Authors should obtain permission to acknowledge from all those mentioned in the 
Acknowledgements. 
Please list the source(s) of funding for the study, for each author, and for the manuscript 
preparation in the acknowledgements section. Authors must describe the role of the 
funding body, if any, in study design; in the collection, analysis, and interpretation of 
data; in the writing of the manuscript; and in the decision to submit the manuscript for 
publication. 
References  
 
All references must be numbered consecutively, in square brackets, in the order in 
which they are cited in the text, followed by any in tables or legends. Reference 
citations should not appear in titles or headings. Each reference must have an individual 
reference number. Please avoid excessive referencing. If automatic numbering systems 
are used, the reference numbers must be finalized and the bibliography must be fully 
formatted before submission. 
Only articles and abstracts that have been published or are in press, or are available 
through public e-print/preprint servers, may be cited; unpublished abstracts, 
unpublished data and personal communications should not be included in the reference 
list, but may be included in the text and referred to as “unpublished data”, “unpublished 
observations”, or “personal communications” giving the names of the involved 
researchers. Notes/footnotes are not allowed. Obtaining permission to quote personal 
communications and unpublished data from the cited author(s) is the responsibility of 
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the author. Journal abbreviations follow Index Medicus/MEDLINE. Citations in the 
reference list should contain all named authors, regardless of how many there are. 
Examples of the Trials reference style are shown below. Please take care to follow the 
reference style precisely; references not in the correct style may be retyped, 
necessitating tedious proofreading. 
Links  
 
Web links and URLs should be included in the reference list. They should be provided 
in full, including both the title of the site and the URL, in the following format: The 
Mouse Tumor Biology Database [http://tumor.informatics.jax.org/mtbwi/index.do] 
Trials reference style 
Style files are available for use with popular bibliographic management software: 
• BibTeX 
• EndNote style file 
• Reference Manager 
Article within a journal  
 
1. Koonin EV, Altschul SF, Bork P: BRCA1 protein products: functional motifs. Nat 
Genet 1996, 13:266-267. 
Article within a journal supplement  
 
2. Orengo CA, Bray JE, Hubbard T, LoConte L, Sillitoe I: Analysis and assessment of 
ab initio three-dimensional prediction, secondary structure, and contacts 
prediction. Proteins 1999, 43(Suppl 3):149-170. 
In press article  
 
3. Kharitonov SA, Barnes PJ: Clinical aspects of exhaled nitric oxide. Eur Respir J, in 
press. 
Published abstract  
 
4. Zvaifler NJ, Burger JA, Marinova-Mutafchieva L, Taylor P, Maini RN: 
Mesenchymal cells, stromal derived factor-1 and rheumatoid arthritis 
[abstract]. Arthritis Rheum 1999, 42:s250. 
Article within conference proceedings  
 
5. Jones X: Zeolites and synthetic mechanisms. In Proceedings of the First National 
Conference on Porous Sieves: 27-30 June 1996; Baltimore. Edited by Smith Y. 
Stoneham: Butterworth-Heinemann; 1996:16-27. 
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Book chapter, or article within a book  
 
6. Schnepf E: From prey via endosymbiont to plastids: comparative studies in 
dinoflagellates. In Origins of Plastids. Volume 2. 2nd edition. Edited by Lewin RA. 
New York: Chapman and Hall; 1993:53-76. 
Whole issue of journal  
 
7. Ponder B, Johnston S, Chodosh L (Eds): Innovative oncology. In Breast Cancer Res 
1998, 10:1-72. 
Whole conference proceedings  
 
8. Smith Y (Ed): Proceedings of the First National Conference on Porous Sieves: 27-30 
June 1996; Baltimore. Stoneham: Butterworth-Heinemann; 1996. 
Complete book  
 
9. Margulis L: Origin of Eukaryotic Cells. New Haven: Yale University Press; 1970. 
Monograph or book in a series  
 
10. Hunninghake GW, Gadek JE: The alveolar macrophage. In Cultured Human Cells 
and Tissues. Edited by Harris TJR. New York: Academic Press; 1995:54-56. [Stoner G 
(Series Editor): Methods and Perspectives in Cell Biology, vol 1.] 
Book with institutional author  
 
11. Advisory Committee on Genetic Modification: Annual Report. London; 1999. 
PhD thesis  
 
12. Kohavi R: Wrappers for performance enhancement and oblivious decision 
graphs. PhD thesis. Stanford University, Computer Science Department; 1995. 
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Appendix 2  
Data extraction form 
Study Title  
Author(s) and Year of Publication  
Participants  
Objective  
Methodology  
Inclusion Criteria  
Results  
Reasons for participation  
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Appendix 3 
Quantitative quality assessment items (adapted from Downs & Black, 1998) 
1. Is the hypothesis, aim or objective of the study clearly described? 
2. Are the main outcomes to be measured clearly described in the Introduction or 
Methods section? 
3. Are the characteristics of the patients included in the study clearly described? 
5. Are the distributions of principal confounders in each group of subjects to be 
compared clearly described? 
6. Are the main findings of the study clearly described? 
7. Does the study provide estimates of the random variability in the data for the main 
outcomes? 
8. Have all-important adverse events that may be a consequence of the intervention been 
reported? 
9. Have the characteristics of patients lost to follow-up been described? 
10. Have actual probability values been reported (e.g. 0.035 rather than <0.05) for the 
main outcomes except where the probability value is less than 0.001? 
11. Were the subjects asked to participate in the study representative of the entire 
population from which they were recruited? 
12. Were those subjects who were prepared to participate representative of the entire 
population from which they were recruited? 
13. Were the staff, places, and facilities where the patients were treated, representative 
of the treatment the majority of patients receive? 
16. If any of the results of the study were based on “data dredging”, was this made 
clear? 
17. In trials and cohort studies, do the analyses adjust for different lengths of follow-up 
of patients, or in case-control studies, is the time period between the intervention and 
outcome the same for cases and controls? 
18. Were the statistical tests used to assess the main outcomes appropriate? 
20. Were the main outcome measures used accurate (valid and reliable)? 
22. Were study subjects in different intervention groups (trials and cohort studies) or 
were the cases and controls (case-control studies) recruited over the same period of 
time? 
26. Were losses of patients to follow-up taken into account? 
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27. Did the study have sufficient power to detect a clinically important effect where the 
probability value for a difference being due to chance is less than 5%? 
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Appendix 4 
The ‘Quality Framework’ by Spencer, Ritchie, Lewis, & Dilon, (2003) 
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Appendix 8 
Guidelines for authors for the journal of Human Reproduction  
 
Scope 
Human Reproduction publishes full length, peer reviewed papers reporting original 
research, as well as opinions, debates and clinical case reports of outstanding originality 
and importance. Mini-reviews forming part of the ‘Developments in Reproductive 
Biology and Medicine’ series are also occasionally published. These articles aim at 
summarizing concisely particularly important and rapidly-developing areas of 
reproductive medicine for which not enough has been published to enable more 
substantive reviews to be written. The majority of ‘Developments’ reviews will 
originate from the journal’s Associate Editors but uninvited contributions are also 
welcomed. 
Papers should be within the recognized broad scope of human reproductive biology and 
reproductive medicine. This includes relevant scientific and clinical aspects of 
reproductive physiology and pathology, reproductive endocrinology and endocrine 
therapies. It also includes andrology, contraception, early pregnancy, embryo 
development, ethical issues, fertilization, gametogenesis, genetic screening (first 
trimester) , genetic diagnosis (pre-implantation), gonadal function, implantation, 
infectious diseases, menstrual disorders, psycho-social issues, reproductive genetics, 
reproductive surgery, reproductive oncology, reproductive epidemiology, and stem cell 
research. Research which would be classified as clearly in the fields of obstetrics or 
gynaecological oncology will not normally be published. 
 
Manuscript length 
Papers should be of a length appropriate for the amount of information they contain. 
Failure to restrict the length of manuscripts, especially Introduction and Discussion 
sections, can negatively influence the reviewers’ and the editor’s decisions. 
 
Style 
Manuscripts should be written using clear and concise English, with English standard 
spelling and conventions. Non English speaking authors are advised to enlist the 
assistance of a native English speaker, familiar with biomedical terminology. The 
editors reserve the right to return without review manuscripts that can not be adequately 
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assessed due to a poor standard of English. For Biochemical and Bacterial terminology 
follow the International Union of Pure and Applied Chemistry (IUPAC) and 
International Union of Biochemistry and Molecular Biology (IUBMB) 
recommendations Genotypes must be italicized; phenotypes should not. 
 
Units of measurement and abbreviations 
Units of measurement should be in Systéme International (SI) units and those 
recommended by the IUPAC should be used wherever possible. Standard units of 
measurements and chemical symbols of elements may be used without definition in the 
body of the paper. Abbreviations should be given in brackets after their first mention in 
the text, and used thereafter. For centrifugation rates give g values rather than rpm, as 
this will vary according to rotor diameter. 
 
Format 
Double spacing on one side of the paper only. Number each page top right. Number 
lines. Avoid underlining. Differentiate clearly letters O, I and numbers 0, 1. Ensure 
unusual symbols are written clearly. 
 
Structure (listed in order of appearance in the published manuscript) 
Title 
Should not exceed 25 words and should be specific and informative. 
 
Running title 
Should not exceed 50 characters. 
 
Authors 
Give initials and family name of all authors. Declaration of Author’s roles is required at 
submission and this information will be included after the discussion, see below. (Please 
refer to the section ‘To accompany manuscript at submission’ above for more details 
regarding authorship)” 
 
Address 
The department, institution, city and country should be given with postal code for each 
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author. An e mail address will be published for the corresponding author, who should be 
clearly identified. Current addresses should be provided for all authors. 
 
Abstract 
The abstract should be a single paragraph which clearly summarizes the findings of the 
manuscript. Note that online abstracts are published for viewing in isolation to the main 
body of the manuscript and should be self explanatory. The following structured 
headings should be used to divide the text of abstracts: BACKGROUND, METHODS, 
RESULTS and CONCLUSIONS. All papers should clearly describe within the 
BACKGROUND section the background and objective of the study and within the 
METHODS section the design, setting, patients, interventions and main outcome 
measures should be described. Where multiple methodologies have been used, these and 
the results obtained can be presented in sequence in a combined METHODS and 
RESULTS section. Mention of the study’s single most important limitation should be 
made in the CONCLUSION section of the abstract. Citations should not appear in the 
abstract. A structured abstract format is not applicable to Debates, Opinions and Case 
Reports. 
 
Key words 
Up to five key words must be supplied by the author. The key words, together with the 
title and abstract, are used for online searches. They should therefore be specific and 
relevant to the paper. 
 
Introduction 
The introduction should be limited to the specific background necessary to show the 
importance and context of the current study. The objective of the study should be 
clearly stated in the final paragraph of the Introduction. 
 
Materials and methods 
The names, town and country of origin of all suppliers should be included. 
 
Results 
Unnecessary overlap between tables, figures and text should be avoided.  
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Discussion 
The discussion should begin with a succinct statement of the principal findings, outline 
the strengths and weaknesses of the study, discuss the findings in relation to other 
studies, provide possible explanations and indicate questions which remain to be 
answered in future research. 
 
Author’s roles Please give details for the contributions of each of the authors, including 
participation in study design, execution, analysis, manuscript drafting and critical 
discussion. 
 
Acknowledgements 
Personal acknowledgements should precede those of institutions or agencies. 
 
Funding 
With respect to funding of research, in line with the World Association of Medical 
Editors (WAME) guidelines, http://www.wame.org/wamestmt.htm#fundres the journal 
considers it the responsibility of the author to protect the integrity of the research record 
from bias related to the source of funding by fully declaring all sponsorships, the roles 
played by sponsors in the research as well as institutional affiliations and relevant 
financial ties. These should be listed in the manuscript after the ‘Acknowledgements’.  
 
Reference citations within the text 
Authors are responsible for the accuracy of the references. Each reference should be 
cited by author and date. If there are two authors please list both, if more than two 
please use first author then et al. Permission to cite personal communications (J.Smith, 
personal communication) should be obtained by the corresponding author. Unpublished 
data should be cited as (unpublished data) and should not be included in the reference 
list. Either of the above should be used only when essential. 
 
References to papers accepted for publication, but not yet published, should be cited as 
such in the reference list e.g. Bloggs A (2007) In vitro fertilization. Hum Reprod, in 
press. 
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Reference list 
Please use the following style. Note that correct punctuation and journal abbreviations 
must be used in order to run the search programs used to edit the manuscript. 
Incorrectly types references take a lot of time to correct, for which we reserve the right 
to charge. Up to 10 authors should be included after which et al. should be used. Refer 
to the following examples.  
Authors. Title. Journal date; issue: pg-pg 
 
Biggers JD and McGinnis LK. Evidence that glucose is not always an inhibitor of 
mouse preimplantation development in vitro. Hum Reprod 2001:16:153-163. 
 
Gekas J, Thepot F, Turleau C, Siffroi JP, Dadaoune JP, Briault S, Rio M, Bourouillou 
G, Carre Pigeon F, Wasels R et al. Chromosomal factors of infertility in candidate 
couples for ICSI: an equal risk of constitutional aberrations in women and men. Hum 
Reprod 2001;16: 82-90. 
 
Elliot WH and Elliot DC. Biochemistry and Molecular Biology. 2nd edn, 2001.Oxford 
University Press, Oxford, UK. 
 
Warren MA, Li TC and Klentzeris D. Cell biology of the endometrium: histology, cell 
types and menstrual changes. In Chard T and Grudzinskas JG (eds) The Uterus. 1994. 
Press Syndicate of the University of Cambridge, Cambridge, UK, pp.94-125. 
 
Tables 
Each table should be numbered consecutively with Roman numerals. Please avoid 
complex constructions. Each item of data should be in a separate cell and should be 
produced using Word or Excel format. Each table should be self explanatory and 
include a brief descriptive title. Footnotes to the table indicated by superscript lowercase 
letters are acceptable but should not include extensive experimental detail. Reference to 
the tables in the text should be sequential (ie Table I, II etc). Do not include more tables 
than is absolutely necessary – non-essential tables may be judged as being suitable for 
online-only publication. 
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Figure legends 
Each legend must be self contained, with all symbols and abbreviations used in the 
figure defined. 
 
Figures 
Full instructions on preparing the figures are available as part of the online submission 
instructions. Please follow these instructions carefully as failure to do so will delay 
publication of your manuscript (please note: the editors reserve the right to charge for 
extensive changes). In preparing graphs authors should avoid background tints and 3D 
effects and maintain a consistent label size and aspect ratio (the x/y axis ratio) 
throughout a paper. Figure and axes titles should be clear and NOT in bold text. Do not 
include more figures than is absolutely necessary – non-essential figures may be judged 
as being suitable for online-only publication. 
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Appendix 9 
Ethical approval letter 
(R & D approval not required due to the use of a non-clinical sample) 
 
 
POSTGRADUATE MEDICAL INSTITUTE 
(IN ASSOCIATION WITH HULL YORK MEDICAL SCHOOL) 
DL/JBK 
 
 
6 April 2009 
 
 
Mr C Sanderson 
Department of Clinical Psychology 
Hertford Building 
The University of Hull 
Cottingham Road 
HULL   HU6 7RX 
 
 
Dear Chris 
 
Thank you for attending the Faculty Ethics Committee meeting on Tuesday, 31 March 
2009 and explaining so coherently your research proposal to the committee.  I am 
pleased to report that the committee approved your proposal with the following 
recommendations; 
 
1. Clarification is required on the consent form regarding the term ‘convenience 
sampled study’ 
2. The documentation needs to reflect that this research is being conducted 
through the Postgraduate Medical Institute (PGMI) and not HYMS.  
 
May I take this opportunity of wishing you every success with your research. 
 
Yours sincerely 
 
 
 
DOMINIC LAM 
Chair – PGMI Ethics Committee 
 
 
Professor Nicholas D Stafford MB FRCS 
 Director – Postgraduate Medical Institute 
 Postgraduate Medical Institute, Hertford Building (Room 203) 
 The University of Hull 
 Hull, HU6 7RX, UK 
 T: +44 (0) 1482 465348/464213 
 F: +44 (0) 1482 463421 
 N.D.Stafford@hull.ac.uk 
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Appendix 10 
Internet advertisement picture used for survey recruitment 
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Appendix 11 
Information sheet 
 
Masculinity, Altruism and Participation in Male Reproductive Health Studies 
INFORMATION SHEET   
Thank you for showing an interest in this project.  Please read this information sheet 
carefully before deciding whether to take part. If you decide not to take part, there will 
be no disadvantage to you of any kind and we thank you for considering our request.   
What is the Aim of the Project? 
The aim of this project is to measure participant’s responses on a masculinity and 
altruism questionnaire and assess if these measures are related on a participants decision 
to participate in a reproductive health study. 
Why have you been asked? 
You have been asked to participate in this study as you are male. 
What will you have to do? 
You will be asked to fill out a questionnaire and if you would like to consent to take 
part in a reproductive health experiment. This should take about 10 minutes.  You can 
fill out only the online questionnaire and then afterwards choose if you would like to 
participate in a reproductive health study and an interview about your experiences. 
Potential participants are advised that they can complete the online questionnaire only 
and do not have to take part in the reproductive health study.       
Please be aware that you may decide not to take part in the project without any 
disadvantage to yourself of any kind. 
Can I change my mind and withdraw from the project? 
You may withdraw from participation in the project at any time whilst filling out the 
questionnaire and without any disadvantage to yourself of any kind. Once the 
questionnaire has been completed, the data is stored anonymously and therefore cannot 
be withdrawn.  
What data or information will be collected and what use will be made of it? 
Responses from the questionnaires and information such as your age, education and 
family status will be collected anonymously. No names or identifiable information will 
be recorded.   
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All information collected will be compared together to assess if it has any relevance to 
men’s choice to participate in a reproductive health experiment.   
The information will be used to see if certain personality traits influence a men’s 
decision to participate in a reproductive health study. This may help to make 
reproductive health studies for males more accessible and therefore increase 
participation. Higher participation rates will inevitably help to increase the 
understanding of male reproductive health therefore facilitating the development of new 
interventions for infertility, sexual dysfunction and sexually transmitted diseases.         
The results of the project may be published but participants can be assured of 100% 
anonymity.  
 
What if I have any questions? 
If you have any questions about our project, either now or in the future, please feel free 
to contact: 
 
Chris Sanderson 
The Department of Clinical Psychology 
Hertford Building 
The University of Hull 
Cottingham Road 
07852134817 
C.J.Sanderson@2007.Hull.ac.uk 
 
This project has been reviewed and approved by the Post Graduate Medical Institute 
Ethics Committee, The University of Hull.  
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Appendix 12 
Consent form 
 
 
Consent Form the study 
 
Participation in this project is voluntary. 
 
You are free to withdraw from this project at any time without any disadvantage. 
 
The results of this project may be published but participants can be assured of 100% 
anonymity. 
 
 
Chris Sanderson  
Trainee Clinical Psychologist  
Department of Clinical Psychology  
The University of Hull  
Email: C.J.Sanderson@2007.Hull.ac.uk 
 
This project has been reviewed and approved by the Post Graduate Medical Institute 
Ethics Committee, The University of Hull. 
 
 
*1. Please read the information given above 
 
▀ I agree to take part in the survey 
 
*2. You must be over 18 to take part in this study. 
 
▀ I am over 18 
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Appendix 13 
Internet survey questions converted to text format  
 
Survey items were randomised for the study and dimension titles removed. Dimension 
titles are included here to report each dimensions items on the MQ.    
 
What is your gender? 
• Male / Female (only males continue) 
 
1. What is your age? 
• 18-27 
• 28-37 
• 38-47 
• 48-57 
• 58-67 
• 67 + 
 
2. What is the highest level of educational qualifications you achieved / have achieved 
so far? 
• SAT’s (year 9) 
• GCSE’s 
• NVQ 
• Vocational course / apprentice 
• University Graduate 
• Masters / PhD 
 
3. Where are you from? 
• United Kingdom 
• Europe 
• Africa 
• Asia 
• Americas 
• Australasia 
 
4. How would you class your ethnicity? 
• White 
• Mixed  
• Asian 
• Black 
• Chinese 
• Other 
 
 
5. What is your relationship status? 
• Single 
• In a long term relationship / married 
• Divorced   
• widowed 
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6. Do you have any children? 
• No 
• Yes  
 
7. How religious do you say you are? 
Not at all  1(A) 2(B) 3(C) religious | | | 4(D) 5(E) | 6(F) 7(G) Strongly religious 
 
DIMENSION 1: Physiological Energy—Arousal. Tension, and Aggressive 
Tendencies 
8. In terms of your experiences in society, how desirable has it been for you to be 
aggressive? 
Strongly 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Strongly 
undesirable      desirable 
 
9. In terms of your experiences in society, how desirable has it been for you to be 
assertive? 
Strongly 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Strongly 
Undesirable     desirable 
 
10. In terms of your experiences in society, how desirable has it been for you to be 
competitive? 
Strongly 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Strongly 
undesirable      desirable 
 
11. In terms of your experiences in society, how desirable has it been for you to be 
dominant? 
Strongly 1(A) 2(B) 3(C) 4(D) 5(F) 6(F) 7(G) Strongly 
undesirable      desirable 
 
DIMENSION 2: Physical Characteristics—Bodily Shape and Size 
 
12. When you are compared to others of your own sex, how often do you think you are 
perceived or treated as more physically muscular (i.e., taller, stronger) than others of 
your own sex? 
1(A) 2(B) 3(C) 4(D) • 5(E) 6(F) 7(G) 
Never     Always 
 
13. When you think about how others see and respond to your own body shape, how 
do you think they characterize your body? 
Extremely 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Extremely 
lean       obese 
 
14. When you think about how others hear and respond to the quality of your voice, 
how do you think they characterize it? 
Extremely 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Extremely 
low-pitched      high-pitched 
 
15. When you think about how others hear and respond to the quality of your voice, 
how do you think they characterize it? 
Extremely 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Extremely 
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emotional      factual 
 
DIMENSION 3: Gender-Related Socio-cultural Roles 
 
16. How strongly do you see yourself as a fan of your favourite sports team (it can be 
any sport)?  
Not at all 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Extremely enthusiastic       
enthusiastic 
 
17. How strongly do your friends see you as a fan of your favourite sports team (it can 
be any sport)?  
Not at all 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Extremely 
enthusiastic      enthusiastic 
 
18. During the season, how closely do you follow your favourite sports team (it can be 
any sport) via any of the following: a) in person or on television, b) on the radio, and/or 
c) television news or a newspaper? 
1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) 
Never     Everyday 
 
19. How often do you display your favourite sports team’s (it can be any sport) name or 
insignia at any of the following: a) your place of work, b) where you live, and/or c) on 
your clothing? 
1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) 
Never     Always 
 
DIMENSION 4: Idealized Gender 
 
20. When you think about society’s definition of the “masculine man” (as it is emerging 
in television and newspaper advertisements), how powerful do you think this image is? 
Extremely 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Extremely 
strong       weak 
 
21. When you think about the definition of the “masculine man” that is emerging in 
your local environment or your immediate culture, how powerful do you think this 
image is?  
Extremely 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Extremely strong  
weak 
 
22. When you think of your current or most recent sexual partner, regardless of whether 
or not the partner is male or female, you characterize your sexual image and style as: 
Less masculine 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) More masculine than your partner 
than your partner 
 
23. When you think of your current or most recent sexual partner and how other people 
reacted or responded to you and your partner as a couple, other people tended to treat 
you as:  
Less masculine 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) More masculine than your partner 
than your partner 
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DIMENSION 5: Sexual Preference 
 
24. In terms of your choice of sexual partners, what is your sexual preference? 
Always the 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Always the 
same sex      opposite sex 
 
25. When you think about your last few sexual fantasies (in your dreams and perhaps 
even in day dreams), were you thinking about the same or opposite sex? 
Always the 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Always the 
same sex       opposite sex 
 
26. When you focus just on what gives you physical satisfaction during sex, to what 
degree is the sex of your partner important? 
Strongly 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Strongly 
important      unimportant 
 
27. When you focus just on what gives you emotional or psychological pleasure during 
sex, to what degree is the sex of your partner important? 
Strongly 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Strongly 
important      unimportant 
 
DIMENSION 6: Subjective Gender-Identity 
 
28. When you think of or imagine the sexual role that you generally have of yourself, 
you think of yourself as: 
Never 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Highly 
masculine      masculine 
 
29. When you think of or imagine the sexual role that your friends have of you, your 
friends treat you as: 
Never 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Highly 
masculine      masculine 
 
30. When you think of or imagine the sexual role that your parents have of you, your 
parents treat you as: 
Never 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Highly 
masculine      masculine 
 
31. When you think of or imagine the sexual role that strangers have of you, strangers 
treat you as: 
Never 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Highly 
Masculine     masculine 
 
DIMENSION 7: Gender-Related Age Identity 
 
32. How often do you feel as if you are sexually immature? 
1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) 
Never     Always 
 
33. How often do others treat you as sexually immature? 
1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) 
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Never      Always 
 
34. How often do you feel as if you are too old to enjoy or engage in sexual relations? 
1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) 
Never      Always 
 
35. How often do others treat you as if you are too old to enjoy or engage in sexual 
relations? 
1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) 
Never     Always 
 
DIMENSION 8: Gender-Related Racial and National Identities 
 
36. How often do you feel you are restricted sexually because of your race and/or 
nationality? 
1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) 
Never     Always 
 
 
37. How often do others treat you as restricted sexually because of your race and/or 
nationality? 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) 
Never       Always 
 
38. How often do you feel society (e.g., in television and magazine advertising) is 
restricting you sexually because of your race and/or nationality?  
1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G)  
Never     Always 
 
39. How often do you feel that forces or factors in your local environment or your 
immediate culture are restricting you sexually because of your race and/or nationality? 
1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) 
Never    Always 
 
DIMENSION 9: Lust 
 
40. How frequently do you want sex?  
Less than once a month 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) More than once a day 
 
41. How important do you think it is for “romance” (i.e., affection, love, and intimacy) 
to be established before orgasm?  
Not at all  1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Very important 
 important 
 
42. What kind of body stimulation do you prefer when having sex?  
Genital 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Full body contact  
only contact 
 
43. How much erotic touching or foreplay before orgasm do you prefer?  
Very 1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G) Very minimal  
extensive 
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DIMENSION 10: Male Eroticism 
 
44. To what degree do you think society (e.g., in television and magazine advertising) 
uses a man’s weight, muscle tone, and overall physical appearance to determine how 
masculine or manly a man is?  
1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G)  
Never     Always 
 
45. To what degree do you think a man’s weight, muscle tone, and overall physical 
appearance determine how masculine or manly a man is?  
1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G)  
Never     Always 
 
46. To what degree do you think society (e.g., in television and magazine advertising) 
uses a man’s grooming (e.g., after shave, cologne, and deodorant), clothes, hair style, 
and fashion sense to determine how masculine or manly a man is?  
1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G)  
Never     Always 
 
47. To what degree do you think a man’s grooming (e.g., after shave, cologne, and 
deodorant), clothes, hair style, and fashion sense determine how masculine or manly a 
man is?  
1(A) 2(B) 3(C) 4(D) 5(E) 6(F) 7(G)  
Never     Always 
 
Altruism Scale 
 
48. I have helped push a stranger’s car out of the snow 
 
49. I have given directions to a stranger 
 
50. I have made change for a stranger 
 
51. I have given money to a charity 
 
52. I have given money to a stranger who needed it (or asked me for it). 
 
53. I have donated goods or clothes to a charity 
 
54. I have done volunteer work for a charity 
 
55. I have donated blood 
 
56. I have helped carry stranger’s belongings (books, parcels, etc). 
 
57. I have delayed an elevator and held the door open for a stranger. 
 
58. I have allowed somebody to go ahead of me in a queue (At a bank machine, in the 
supermarket, etc.)  
 
59. I have given a stranger a lift in my car. 
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60. I have pointed out a clerk’s error (in a bank, at the supermarket) in undercharging 
me for an item.  
 
61. I have let a neighbour whom I didn’t know too well borrow an item of some value to 
me (e.g. a dish, tools, etc). 
 
62. I have bought ‘charity’ Christmas cards deliberately because I knew it was a good 
cause.   
 
Pre-ejaculatory fluid study (PES) recruitment poster  
 
 
 
63. Would you be interested in taking part in taking part in this study? 
 
64. What are your reasons FOR participating in the study advertised above?   
 
65. What are your reasons for NOT participating in the study advertised above?   
 
66. How masculine or manly do you think taking part in the reproductive health trial is?  
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Appendix 14 
Descriptions of Dimensions of the Perceived Masculinity Questionnaire (Chesebro & 
Fuse, 2001) 
 
Physiological energy 
Physiological energy compares androgen/testosterone levels to estrogens/progestin 
levels. This dimension deals with the impact of hormonal differences reflected through 
history and culture by asking “how desirable it is to be aggressive, assertive, 
competitive, dominant, or forceful in society.  
 
Physical characteristics 
Physical characteristics explore gender-related physical characteristics like being 
physically larger than women and having deeper voices.  
 
Gender-related Socio-cultural roles  
Gender-related Socio-cultural roles look at the social performance of masculinity as a 
reflection of culture. It explores what roles men are expected to perform in order to be 
perceived as masculine within a given culture and society.  
 
Idealized masculinity  
Idealized masculinity assesses the influence of social masculine constructions, and self- 
and other-perceptions of an individual’s ability to be masculine.  
 
Sexual preference 
Sexual preference assesses sexual orientation, the gender and gender characteristics of 
one’s sexual partner. 
 
Subjective gender-identity 
Subjective gender-identity measures self- and other-perceptions of the self’s 
masculinity. This refers to how masculine one sees one’s self and how one believes 
others see one’s self.  
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Gender- related age identity 
Gender- related age identity refers to “the social, symbolic construction of sexuality 
relative to one’s age”. For instance, prepubescent boys and elderly men are often 
perceived as asexual, even though it is a misnomer that elderly men are less physically 
able to have sex when it is usually a psychological factor.  
 
Gender-related racial and national identities 
Gender-related racial and national identities deal with the stereotypes people use to 
define and characterize what is and is not masculine for a particular race or national 
identity.  
 
Lust 
Lust is a measure of intense sexual desire, which seems to be related to masculinity. 
Higher levels of lusty intentions and behaviour were predicted to positively correlate 
with higher levels of masculinity.  
 
Male eroticism 
Male eroticism was added to “underscore the sensuous, hedonistic, suggestive, 
passionate, and amorous set of characteristics that have become associated with 
masculinity…in marketing and advertising”.  
 
Interpreting Masculinity Scores on the PMQ 47 (Cheesbro & Fuse, 2002).  
Total Masculinity Scores for Males (n = 331) 
1. Average Score:  205.3 
2. Range:  151 to 249 
3. Interpretation: 
 
• Extremely High Masculinity 246 and higher 
• High Masculinity 226 to 245 
• Average Masculinity 186 to 225 
• Low Masculinity 166 to 185 
• Extremely Low Masculinity 165 and lower 
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Means and standard deviations of dimension scores and total score of perceived 
masculinity on the PMQ 47 (All U.S.A. male respondents) (Cheesbro & Fuse, 2002). 
  Sample Mean S.D. 
1. Physiological 
 Energy 
 
360 
 
21.2 
 
3.6 
2. Masculine Physical 
 Characteristics 
 
363 
 
18.5 
 
2.7 
4. Masculine 
            Socio-cultural Roles 
 
362 
 
17.1 
 
6.8 
4. Idealized Version of 
 Masculinity 
 
356 
 
22.0 
 
3.8 
5. Opposite Sex 
 Preference 
 
364 
 
24.5 
 
4.2 
6. Positive Masculine 
 Self-Conception 
 
363 
 
20.7 
 
4.2 
7. Positive Self-
 Conception of Age 
 
361 
 
23.8 
 
3.4 
8. Positive Self-
 Conception of Race 
 
358 
 
23.4 
 
4.9 
 
9. Lustful 
 
355 
 
13.4 
 
3.1 
10. Erotic Male 
 Characteristics 
 
359 
 
20.0 
 
3.9 
TOTAL 331 205.3 20.1 
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Appendix 15 
Ordinal regression output 
SPSS ordinal regression output for dependent variable willingness to take part in the 
PES, factors age, continent, relationship status, number of children, and co-variable 
scores on the self report altruism scale, gender related socio cultural roles and 
physiological energy subscales of the MQ.  
 
Model Fitting Information 
Model -2 Log Likelihooda Chi-Square df Sig. 
Intercept Only 1368.697    
Final 1317.974 50.723 13 .000 
Link function: Logit. 
a. The kernel of the log-likelihood function is displayed. 
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Parameter Estimates 
  
Estimat
e 
Std. 
Error Wald df Sig. 
95% Confidence Interval 
  Lower 
Bound 
Upper 
Bound 
Threshold [Study participation = 1] 2.820 .645 19.096 1 .000 1.555 4.085 
[Study participation = 2] 3.443 .652 27.919 1 .000 2.166 4.720 
[Study participation = 3] 4.295 .662 42.042 1 .000 2.996 5.593 
[Study participation = 4] 5.539 .681 66.089 1 .000 4.204 6.875 
Location Physiological Energy .022 .020 1.166 1 .280 -.018 .062 
Socio cultural roles .026 .011 5.049 1 .025 .003 .048 
Altruism scale .030 .009 10.836 1 .001 .012 .047 
[Children=0] .317 .317 1.000 1 .317 -.304 .938 
[Children=1] .928 .398 5.448 1 .020 .149 1.707 
[Children=2+] 0a . . 0 . . . 
[Relationship= single] .675 .306 4.861 1 .027 .075 1.276 
[Relationship= long term] .290 .302 .918 1 .338 -.303 .883 
[Relationship= married or 
previously married] 
0a . . 0 . . . 
[Continent=Asia & Africa] .014 .386 .001 1 .970 -.742 .771 
[Continent=Americas] .166 .201 .681 1 .409 -.228 .560 
[Continent=Australasia] .676 .296 5.219 1 .022 .096 1.255 
[Continent=Europe] 0a . . 0 . . . 
[Age=18-27] .601 .275 4.758 1 .029 .061 1.141 
[Age=28-37] .268 .386 .482 1 .487 -.489 1.026 
[Age=38-47] .493 .337 2.139 1 .144 -.168 1.154 
[Age=47+] 0a . . 0 . . . 
Link function: Logit. 
a. This parameter is set to zero because it is redundant. 
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Appendix 16 
Spearman’s Rho correlations of AQ and MQ  
 
Correlations 
   Altruism scale 
Spearman’s 
rho 
Altruism scale Correlation Coefficient 1.000 
Sig. (2-tailed) . 
N 463 
Physiological Energy Correlation Coefficient .062 
Sig. (2-tailed) .189 
N 455 
Physical 
Characteristics 
Correlation Coefficient .102* 
Sig. (2-tailed) .029 
N 461 
Socio cultural roles Correlation Coefficient .021 
Sig. (2-tailed) .658 
N 459 
Idealized gender Correlation Coefficient .131** 
Sig. (2-tailed) .005 
N 456 
Sexual preference Correlation Coefficient .020 
Sig. (2-tailed) .673 
N 456 
Subjective Gender 
identity 
Correlation Coefficient .232** 
Sig. (2-tailed) .000 
N 451 
Gender related age 
identity 
Correlation Coefficient .086 
Sig. (2-tailed) .068 
N 454 
Gender related 
national identity 
Correlation Coefficient -.066 
Sig. (2-tailed) .163 
N 455 
Lust Correlation Coefficient -.238** 
Sig. (2-tailed) .000 
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N 459 
Male eroticism Correlation Coefficient .035 
Sig. (2-tailed) .458 
N 454 
 MQ total Correlation Coefficient .046 
Sig. (2-tailed) .355 
N 407 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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Appendix 17 
Interview Schedule 
 
What were your reasons for taking part in the Pre-Cum study? What was your 
motivation? 
 
What things stopped you from taking part in the study? 
 
What was the study like? Was it what you expected?  
 
Would you have preferred a male or female researcher to give your sample to? Would 
you have felt more comfortable if nobody knew your name ….. or if you could have left 
an unlabelled sample on a bench without seeing anyone?  
 
Did this experience change your perception of taking part in similar studies? Would you 
now consider taking part in health studies / medical trials …? 
 
Do you think it’s masculine (manly)  to take part in this study? Did you feel as if your 
masculinity was being tested? Did you have a fear of failure? 
 
What affected your decision to take part? How do you think you’re …. Influenced your 
decision?  
• Physiological Energy 
• Physical Characteristics 
• Male related Socio-cultural Roles 
• Gender-identity 
• Gender-related Age Identity 
• Gender-related Racial and National Identities 
• Lust (Intense or unrestrained sexual craving) 
• Male Eroticism (Sexual excitement) 
• Idealized Masculinity 
• Sexual Preference.  
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Do you think other people see taking part in the study as a masculine (manly) thing to 
do? How important is it that other people see you as masculine (manly)?  
 
Do you think that it is a good thing / seen as a good thing to take part? By whom? 
 
Do you think doing a good deed influenced your decision to take part in the study?  
• Do you know anybody who has reproductive health problems? Did this 
influence your decision to participate?  
• Do you have children / hope to have children in the future? 
• Are you registered as an organ donor? Would you consider donating sperm? 
• Would you require a financial incentive?    
 
Would you discuss the results of a semen evaluation with a partner / friends / family?  
 
How do you think men could be encouraged to take part in the study? What things 
would help (facilitate)? What things would prevent (be barriers)?  
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Appendix 18 
Worked example of Interpretive Phenomenological Analysis: Creation of themes 
A section of transcript from one of the participants is shown here to illustrate each stage 
of the IPA process. The following section is from the beginning of an interview with a 
male who had conducted the PES one week previously.  
 
Extract of transcript 1 
What things made you take part in that, what are your reasons for taking part? 
The money. Pretty easy money really. That was pretty much the main factor I think – 
money. Had a bit of a laugh.  
Quite enjoyable you say, a bit of a laugh? 
I wouldn’t say enjoyable. Maybe afterwards but more nervous to begin with. 
Anticipatory or whatever it is. 
I guess we’ll come on to the things that make you not want to take part. Were 
there any other reasons that made you take part? 
Well it was definitely the money. 
 Ok, so it was all about the money. You talked briefly there about anticipatory, 
what made you not want to take part in the study? 
Failure to perform, something like that. That would have been embarrassing. 
The embarrassment, failure to perform? 
Yeah 
What would be embarrassing about it? 
Just the fact that I knew the people that I was going with. There was more than one of 
us there.  
Embarrassing with your peers? 
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Not necessarily but actually embarrassing even with someone you’ve never met like the 
woman. If I came out it was like…. 
What would have been embarrassing about not being able to perform? 
Inadequacy. 
So it would make you feel inadequate? 
Yeah less of a man. 
Were there any other things that made you not want to take part in this study 
when you think back to before you took part? 
Just because I didn’t know what it was like it was explained to a point what I would be 
doing but the procedure wasn’t made clear until I got there therefore I didn’t know 
whether it would be me with someone else like a doctor or someone or me on my own 
or what to do so until it was explained to me it was a degree of nervousness. 
So nervousness about… 
About the unknown. If I’d have known then it would have been a lot less nerve racking 
I think. 
Were there any other things that made you nervous about the procedure that you 
didn’t know about? 
Just how the sample was going to be taken. Obviously you think of sort of sexual tests 
for things like STDs that doesn’t make you think happy thoughts so if it was anything 
like that I would have been put off and probably wouldn’t have actually done the tests. 
If it was anything to do with a swab I was going to leave. 
 
Stage One Analysis 
Transcripts were read twice to facilitate the researchers understanding of the whole text. 
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Stage Two Analysis  
Individual transcripts were read again. The researcher noted statements of interest, 
commented on the use of particular language, contradictions with other parts of the 
transcripts, and similarities and contradictions with other participants’ transcripts. Stage 
two was also conducted by completed by the researchers supervisor (female, 3 
transcripts), a local Professor in the field of Obstetrics and Gynaecology (male, 2 
transcripts), and a Trainee Clinical Psychologist (female, 5 transcripts).  
Not altruistic. Money as 
rationalising behaviour. 
Conflict with later altruistic 
reasons. Humour. Responses 
brief, reflecting anxiety or 
embarrassment?  
 
Anticipatory anxiety.  
 
 
 
 
 
Other people’s expectations 
of men to perform. To be 
able to produce sperm.  
 
 
Social comparisons.  
 
 
 
What things made you take part in that, what are your reasons 
for taking part? 
The money. Pretty easy money really. That was pretty much the 
main factor I think – money. Had a bit of a laugh.  
Quite enjoyable you say, a bit of a laugh? 
I wouldn’t say enjoyable. Maybe afterwards but more nervous to 
begin with. Anticipatory or whatever it is. 
I guess we’ll come on to the things that make you not want to 
take part. Were there any other reasons that made you take 
part? 
Well it was definitely the money. 
 Ok, so it was all about the money. You talked briefly there 
about anticipatory, what made you not want to take part in the 
study? 
Failure to perform, something like that. That would have been 
embarrassing. 
The embarrassment, failure to perform? 
Yeah 
What would be embarrassing about it? 
Just the fact that I knew the people that I was going with. There 
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Gender influences 
embarrassment.  
 
Masculinity connected to 
socio-cultural belief about 
ability to obtain and 
maintain erection and 
produce sample. 
 
 
 
Fear of the unknown. 
 
 
 
 
 
 
Exposure and reassurance. 
 
 
 
Catastrophic predictions as a 
barrier. Related to other 
stigmatised areas such as 
sexually transmitted 
diseases.    
was more than one of us there.  
Embarrassing with your peers? 
Not necessarily but actually embarrassing even with someone 
you’ve never met like the woman. If I came out it was like…. 
What would have been embarrassing about not being able to 
perform? 
Inadequacy. 
So it would make you feel inadequate? 
Yeah less of a man. 
Were there any other things that made you not want to take 
part in this study when you think back to before you took 
part? 
Just because I didn’t know what it was like it was explained to a 
point what I would be doing but the procedure wasn’t made clear 
until I got there therefore I didn’t know whether it would be me 
with someone else like a doctor or someone or me on my own or 
what to do so until it was explained to me it was a degree of 
nervousness. 
So nervousness about… 
About the unknown. If I’d have known then it would have been a 
lot less nerve racking I think. 
Were there any other things that made you nervous about the 
procedure that you didn’t know about? 
Just how the sample was going to be taken. Obviously you think of 
sort of sexual tests for things like STDs that doesn’t make you 
think happy thoughts so if it was anything like that I would have 
been put off and probably wouldn’t have actually done the tests. If 
it was anything to do with a swab I was going to leave. 
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Stage Three Analysis  
Emerging themes (including the researchers and colleagues interpretations) and other 
transcripts and links to relevant theory were documented in the right margin.  
 
Not altruistic. Money 
as rationalising 
behaviour. Conflict 
with later altruistic 
reasons. Humour. 
Responses brief, 
reflecting anxiety or 
embarrassment?  
 
Anticipatory anxiety.  
 
 
 
 
 
Other people’s 
expectations of men 
to perform. To be able 
to produce sperm.  
 
 
 
Social comparisons.  
 
 
Gender influences 
What things made you take part in that, what 
are your reasons for taking part? 
The money. Pretty easy money really. That was 
pretty much the main factor I think – money. Had a 
bit of a laugh.  
Quite enjoyable you say, a bit of a laugh? 
I wouldn’t say enjoyable. Maybe afterwards but 
more nervous to begin with. Anticipatory or 
whatever it is. 
I guess we’ll come on to the things that make you 
not want to take part. Were there any other 
reasons that made you take part? 
Well it was definitely the money. 
 Ok, so it was all about the money. You talked 
briefly there about anticipatory, what made you 
not want to take part in the study? 
Failure to perform, something like that. That would 
have been embarrassing. 
The embarrassment, failure to perform? 
Yeah 
What would be embarrassing about it? 
Just the fact that I knew the people that I was going 
with. There was more than one of us there.  
Decision making 
process: pros vs. 
cons 
 
 
 
Performance 
anxiety 
Humour as coping.  
 
 
 
 
 
 
 
 
Performance 
anxiety. 
 
 
 
 
Performance 
anxiety; social 
comparisons. 
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embarrassment.  
 
 
Masculinity 
connected to socio-
cultural belief about 
ability to obtain and 
maintain erection and 
produce sample. 
 
 
 
Fear of the unknown. 
 
 
 
 
 
 
 
 
Exposure and 
reassurance. 
 
 
 
 
Catastrophic 
predictions as a 
barrier. Related to 
other stigmatised 
Embarrassing with your peers? 
Not necessarily but actually embarrassing even with 
someone you’ve never met like the woman. If I 
came out it was like…. 
What would have been embarrassing about not 
being able to perform? 
Inadequacy. 
So it would make you feel inadequate? 
Yeah less of a man. 
Were there any other things that made you not 
want to take part in this study when you think 
back to before you took part? 
Just because I didn’t know what it was like it was 
explained to a point what I would be doing but the 
procedure wasn’t made clear until I got there 
therefore I didn’t know whether it would be me with 
someone else like a doctor or someone or me on my 
own or what to do so until it was explained to me it 
was a degree of nervousness. 
So nervousness about… 
About the unknown. If I’d have known then it 
would have been a lot less nerve racking I think. 
Were there any other things that made you 
nervous about the procedure that you didn’t 
know about? 
Just how the sample was going to be taken. 
Obviously you think of sort of sexual tests for things 
like STDs that doesn’t make you think happy 
Stigma. 
 
 
 
 
Performance 
anxiety; 
masculinity. 
 
 
 
 
 
Performance 
anxiety; 
catastrophic 
predictions.   
 
 
 
 
 
 
Performance 
anxiety; exposure. 
 
 
Catastrophic 
predictions. 
 
Stigma.  
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areas such as sexually 
transmitted diseases.    
thoughts so if it was anything like that I would have 
been put off and probably wouldn’t have actually 
done the tests. If it was anything to do with a swab I 
was going to leave. 
 
Coping; avoidance 
  
 
Stage Four Analysis  
Quotes from all participants’ transcripts were grouped into relevant themes to enable 
comparisons. Emerging themes were discussed with colleagues and an expert in the 
field who had also analysed the transcripts and two participants. This provided a process 
of peer, expert and member validation for the emerging themes.   
 
Emerging Theme Supporting Quotes 
Decision making 
process 
 
Stigma 
 
 
 
 
Fear of the unknown  
 
 
 
 
 
“That was pretty much the main factor I think – money.” 
 
 
“…but actually embarrassing even with someone you’ve never 
met like the woman” 
“Obviously you think of sort of sexual tests for things like STDs 
that doesn’t make you think happy thoughts” 
 
“Just because I didn’t know what it was like it was explained to 
a point what I would be doing but the procedure wasn’t made 
clear until I got there therefore I didn’t know whether it would 
be me with someone else like a doctor or someone or me on my 
own or what to do so until it was explained to me it was a 
degree of nervousness.” 
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Performance anxiety; 
feeling less of a man 
 
Coping strategies; 
Humour 
 
Avoidance 
 
“What would have been embarrassing about not being able 
to perform? Inadequacy. So it would make you feel 
inadequate? Yeah less of a man.” 
 
“Had a bit of a laugh.”  
 
“If it was anything to do with a swab I was going to leave.” 
 
 
Stage Five Analysis  
Connections between themes and across transcripts were made. Super-ordinate themes 
were compared across transcripts and included if they were present in over half the 
sample.  
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Appendix 19 
Reflective Statement 
Introduction 
This statement reflects upon all aspects of the research process, including the 
formulation of research questions, the choice of methodology, the process of conducting 
a systematic literature review, and the process of conducting both a quantitative and 
qualitative study. I aim to give a personal account of the research process, reflect upon 
decisions made and how completing this research project has influenced my overall 
understanding of research.   
 
Formulation of a research question 
The idea to undertake a research topic in the area of male reproductive health was 
initially proposed to me by a local Professor in the field of Obstetrics and Gynaecology. 
He described a paucity of males participating in a local reproductive health trial (RHT). 
A subsequent review of the literature revealed very little research into reasons 
underlying this phenomenon. The few studies I found reported that low participation 
rates in male RHTs were an international problem and much lower in comparison to 
females. I was initially interested in the psychological factors that underpin gender 
differences. In reflection, I had already fostered an interest in gender differences and the 
social construction of masculinity, being the only male in my class and entering a 
female dominated profession. I have also always been amazed by the capacity of people 
to cope with medical conditions, in particular reproductive health problems, and 
reflected on how I would feel in the same situation. From the outset, I assumed that 
research in this area was a worthwhile endeavour. Therefore, the decision to research 
gender differences in RHTs provided an opportunity to produce both a clinically 
relevant research project and research a topic of interest.  
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Intuition suggested that altruism is an important factor in the decision to participate in 
clinical trials and a literature search confirmed this (Trauth, Musa, Siminoff, Jewell, & 
Ricci, 2000). Unselfish displays of generosity have continually moved me and I have 
been fascinated by causes of altruistic behaviours from social psychology modules 
during undergraduate degree. I therefore decided to research the influence of 
masculinity and altruism on male RHT participation. In retrospect, choosing a topic of 
interest was a wise decision as it gave me the motivation to overcome various hurdles.         
 
Choice of methodology      
The choice of methodology posed various theoretical difficulties for me. I believe that 
masculinity and altruism have quite idiosyncratic meanings, thus I felt slightly awkward 
when attempting to quantify them. Following the peer review process with colleagues at 
university, I decided to use both quantitative and qualitative methodologies. 
Quantitative methods allowed for hypotheses about the influence of masculinity and 
altruism to be tested on a large sample of men. At the same time, a qualitative analysis 
provided a deeper understanding of individuals’ experiences of RHTs and the meanings 
they attached to masculinity and altruism. Initially, I was concerned a mixed 
methodology would mean extra work and possibly affect the overall quality of each 
study. However, I believe that allowing participants to give qualitative comments 
allowed an important process of triangulation, therefore giving me more confidence to 
draw conclusions from results of the study. Instead of hindering my project, I think that 
using mixed methods allowed for a more rounded understanding of the topic.    
 
Systematic Literature Review  
Initially I (probably foolishly) thought conducting a systematic literature review would 
be relatively simple. However, I found myself struggling at various points throughout 
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the process, most notably the iterative process of implementing search strategies, 
refining inclusion criteria and conducting quality assurance checks. The choice of 
question for the review may appear quite ‘dry’ to other readers and at times, I too felt 
slightly detached from the review. On reflection, I wonder if the void of feeling towards 
the review reflected the state of mind of participants portrayed from the articles 
reviewed. As the rationale of the study suggests, most people do not consider taking 
part in clinical trials in day-to-day life.  
 
I believe that the findings of the review provided a sound platform to complete both 
studies. The thought that each element of the thesis complement each other also 
provides some satisfaction. Now that I have completed one systematic review, I feel that 
I have both the skills and inclination to conduct systematic reviews in the future. I also 
feel that next time I conduct a review, the hurdles I encountered for this paper will not 
feel so high.   
 
The review was written in accordance with the guidelines for authors outlined by the 
journal ‘Trials’. I chose Trials as it publishes papers that ‘encompass all aspects of the 
performance and findings of randomized controlled trials’, has a relatively high impact 
factor (2.02) and ‘offers a way to make data both freely available and highly visible to 
trialists worldwide’. Trials offered the opportunity to report findings to researchers who 
would benefit most from the findings without being restricted by stringent guidelines 
and word limits, more focused on reporting of clinical trials. 
 
Ethics 
The process of obtaining ethical approval from the Post Graduate Medical Institute 
seemed to be much more straightforward than reports from my peers who went through 
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NHS ethics boards. However, the process of obtaining ethical approval did provide a 
useful space to consider the methodology of the study.  
 
Empirical study 
I remember having mixed feelings about conducting a research topic in the area of male 
reproductive health. On the one hand, I felt a sense of pride about conducting research 
into a worthwhile yet seemingly unpopular area. At the same time, I recall a sense of 
apprehension and embarrassment about presenting proposals to study male reproductive 
health. In retrospect, feelings of embarrassment were partly fuelled by my perceived 
reactions of others and the jokes that people made. Interestingly, these experiences 
paralleled those of men thinking about participating in RHTs in both studies. When men 
were asked to think about RHTs, they were torn between feeling a ‘warm glow’ from 
helping medical science and shame associated with conducting a ‘taboo act in public’. 
Participants often constructed RHTs as particularly stigmatised, coping with the shame 
of stigma with humour. I think discussing experiences of participation with participants, 
participating in the PES and reflecting on my own feelings helped to broaden my 
appreciation of male RHTs. Similar to participants, exposure to the topic helped me to 
feel much more relaxed talking about reproductive health. I believe that feeling more 
comfortable talking about sexuality and sexual difficulties has enhanced my clinical 
work, leading to more open discussions of patients’ reproductive health where 
appropriate. Not having the opportunity to have more face-to-face contact with people is 
one of my main regrets from this experience.   
 
Study 1 
Finding a suitable way of measuring masculinity and altruism was my next significant 
challenge. A review of the literature suggested the Self Report Altruism Scale 
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(Rushden, Chrisjohn, & Fekken, 1981) has been widely used and seemed to have good 
reliability and validity, therefore the decision to use this scale was relatively easy. The 
choice of masculinity scale was much more difficult. A review of relevant literatures 
suggested various masculinity scales. I narrowed my choices down to the Perceived 
Masculinity Scale (MQ: Chesebro & Fuse, 2001) and the Gender Role Conflict Scale 
(GRCS: O'Neil, Helms, Gable, David, & Wrightsman, 1986). In the end, I chose the 
MQ due to the author’s extensive research into modern constructions of masculinity and 
the variety of dimensions it covered.  
 
Due to the exploratory nature of correlating dimensions of masculinity with willingness 
to take part in a RHT, I was quite resistant to lose dimensions of the MQ.  Therefore, 
initial power calculations suggested that a sample size of 500 was required. At the 
outset, I was quite daunted yet slightly excited about the prospect of recruiting such a 
high number of participants. Enlisting the help of a friend who worked in internet 
advertising, the use of Survey Monkey and internet advertising made recruiting the 500 
possible. There was inherent bias in the study due to the self-selection of participants 
and the style of advertisement. Nevertheless, it is likely that self-selected participants 
are more likely to participate in a trial and therefore representative of the target sample. 
Analysis of the results showed significant findings that triangulated with participants’ 
comments and previous research. Even so, I felt that a deeper understanding of the area 
could have been achieved and therefore I am glad that I decided to write a qualitative 
paper on men’s experience of clinical trials.  
 
Study 2 
I was initially quite nervous about conducting a qualitative study, as I was unsure about 
‘how to do it’. I had always felt comfortable with statistical analysis after completing an 
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A level in maths and use of statistics during my undergraduate psychology degree. 
However, I found the process of conducting an Interpretive Phenomenological Analysis 
(IPA) both enlightening and enjoyable. Carrying out an IPA study gave me an insight 
into the depth of meaning and understanding that the methodology allows. Whilst 
researching concepts such as masculinity I became acutely aware of my own social 
constructions and the impact these had on the study. Hence, I found the validation of 
themes process with both female and male colleagues both helpful and reassuring. I 
believe that I leant an incredible amount from completing an IPA study from start to 
finish and now feel much more confident about conducting qualitative research in the 
future.  By completing an IPA study, I now have a much greater understanding of what 
is required for all stages of the process, such as interviews and analysis. I hope to have 
the opportunity to implement these skills again in the future.     
 
Conclusion     
I am satisfied that I have learnt so much from all aspects of my doctoral project. 
Although at times it has been challenging and frustrating, I feel that I am now equipped 
to go on and do further research. Reflecting on my experiences along the way has 
helped me to see, often frustratingly, how many of the hurdles could have been 
overcome in a much more efficient manner.  
 
 
 
